• Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. J. Clin. Pharm. Ther. 27: 391-401 (2002). *

• Abel S, Yang Y, Waring JF. Development of an in vitro gene expression assay for predicting hepatotoxicity. ALTEX 23: S326-S331 (2006).

• Adamopoulos AB. Inflammatory bowel disease (IBD) and the liver. Annals of Gastroenterology 19: 146-151 (2006). *

• Ahmad Z. The uses and properties of almond oil. Complement. Ther. Clin. Pract. 16: 10-12 (2010).

• Ahmed S, Leo MA, Lieber CS. Interactions between alcohol and beta-carotene in patients with alcoholic liver disease. Am. J. Clin. Nutr. 60: 430-436 (1994). *

• Aithal GP. Dangerous liaisons: drug, host and the environment. J. Hepatol. 46: 995-998 (2007). *

• Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JBS, Alexander G, Kenna JG, Caldwell J, Day CP. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39: 1430-1440 (2004). *

• Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 44: 731-735 (1999). *

• Ajit C, Suvannasankha A, Zaeri N, Munoz SJ. Terbinafine-associated hepatotoxicity. Am. J. Med. Sci. 325: 292-295 (2003).

• Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG. Allopurinol hepatotoxicity. Report of two cases and review of the literature. Ann. Intern. Med. 95: 588-590 (1981).

• Alam I, Ferrell LD, Bass NM. Vanishing bile duct syndrome temporally associated with ibuprofen use. Am. J. Gastroenterol. 91: 1626-1630 (1996).

• Alexander P, Roskams T, Van Steenbergen W, Peetermans W, Desmet V, Yap SH. Intrahepatic cholestasis induced by amoxicillin/clavulanic acid (Augmentin): a report on two cases. Acta Clin. Belg. 46: 327-332 (1991).

• Alexopoulou L, Kranidioti K, Xanthoulea S, Denis M, Kotanidou A, Douni E, Blackshear PJ, Kontoyiannis DL, Kollias G. Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. Eur. J. Immunol. 36: 2768-2780 (2006). *

• Ali T, Srinivasan N, Le V, Rizvi S. Alpha-methyldopa hepatotoxicity in pregnancy. J. Coll. Physicians Surg. Pak. 19: 125-126 (2009).

• Alipour M, Omri A, Smith MG, Suntres ZE. Prophylactic effect of liposomal N-acetylcysteine against LPS-induced liver injuries. J. Endotoxin Res. 13: 297-304 (2007). *

• Allemand H, Pessayre D, Descatoire V, DeGott C, Feldmann G, Benhamou JP. Metabolic activation of trichloroethylene into a chemically reactive metabolite toxic to the liver. J. Pharmacol. Exp. Ther. 204: 714-723 (1978).

• Almasio P, Bortolini M, Pagliaro L, Coltorti M. Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis. Drugs 40 Suppl. 3: 111-123 (1990).

• Alnounou M, Munoz SJ. Nutrition Issues In Gastroenterology, Series #37. Nutrition concerns of the patient with primary biliary cirrhosis or primary sclerosing cholangitis. [http://www.healthsystem.virginia.edu/internet/digestive-health/nutritionarticles/April2006.pdf] Practical Gastroenterology April 2006: 92-100 (2006). *

• Alvaro D, Gigliozzi A, Piat C, Carli L, Bini A, La Rosa T, Furfaro S, Capocaccia L. Effect of S-adenosyl-L-methionine on ethanol cholestasis and hepatotoxicity in isolated perfused rat liver. Dig. Dis. Sci. 40: 1592-1600 (1995).

• Amital H, Arnson Y, Chodick G, Shalev V. Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate. Rheumatology (Oxford) 48: 1107-1110 (2009).

• Anand SS, Mumtaz MM, Mehendale HM. Dose-dependent liver regeneration in chloroform, trichloroethylene and allyl alcohol ternary mixture hepatotoxicity in rats. Arch. Toxicol. 79: 671-682 (2005). *

• Andrade RJ, Lucena MI, Alonso A, Garcia-Cores M, Garcia-Ruiz E, Benitez R, Fernandez MC, Pelaez G, Romero M, Corpas R, Duran JA, Jimenez M, Rodrigo L, Nogueras F, Martin-Vivaldi R, Navarro JM, Salmeron J, de la Cuesta FS, Hidalgo R. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 39: 1603-1612 (2004). *

• Andrade RJ, Lucena MI, Kaplowitz N, Garcia-Munoz B, Borraz Y, Pachkoria K, Garcia-Cortes M, Fernandez MC, Pelaez G, Rodrigo L, Duran JA, Costa J, Planas R, Barriocanal A, Guarner C, Romero-Gomez M, Munoz-Yague T, Salmeron J, Hidalgo R. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 44: 1581-1588 (2006). *

• Andrade RJ, Robles M, Fernandez-Castaner A, Lopez-Ortega S, Lopez-Vega MC, Lucena MI. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J. Gastroenterol. 13: 329-340 (2007). *

• Andres D, Bautista M, Cascales M. Attenuation of cyclosporine A toxicity by sublethal heat shock. Role of catalase. Biochem. Pharmacol. 69: 493-501 (2005). *

• Angulo P. Use of ursodeoxycholic acid in patients with liver disease. Curr. Gastroenterol. Rep. 4: 37-44 (2002).

• Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin. Liver Dis. 21: 81-88 (2001).

• Anke J, Ramzan I. Kava hepatotoxicity: are we any closer to the truth? Planta Med. 70: 193-196 (2004).

• Ansari A, Elliott T, Baburajan B, Mayhead P, O'Donohue J, Chocair P, Sanderson J, Duley J. Long term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment. Pharmacol. Ther. 28: 734-741 (2008). *

• Ansari A, Elliott T, Baburajan B, Mayhead P, O'Donohue J, Chocair P, Sanderson J, Duley J. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment. Pharmacol. Ther. 28: 734-741 (2008). *

• Ansari A, Elliott T, Fong F, Arenas-Hernandez M, Rottenberg G, Portmann B, Lucas S, Marinaki A, Sanderson J. Further experience with the use of 6-thioguanine in patients with Crohn's disease. Inflamm. Bowel Dis. 14: 1399-1405 (2008). *

• Ansede JH, Smith WR, Perry CH, St Claire RL, Brouwer KR. An in vitro assay to assess transporter-based cholestatic hepatotoxicity using sandwich-cultured rat hepatocytes. Drug Metab. Dispos. Nov 12 [Epub ahead of print] (2009). *

• Anstey AV, Hift RJ. Liver disease in erythropoietic protoporphyria: emerging insights and their implications for management. Gut 56: 1009-1018 (2007). *

• Aparicio JL, Duhalde-Vega M, Loureiro ME, Retegui LA. The autoimmune response induced by mouse hepatitis virus A59 is expanded by an hepatotoxic agent. Int. Immunopharmacol. 9: 627-631 (2009).

• Arseculeratne SN, Gunatilaka AA, Panabokke RG. Studies on medicinal plants of Sri Lanka: occurrence of pyrrolizidine alkaloids and hepatotoxic properties in some traditional medicinal herbs. J. Ethnopharmacol. 4: 159-177 (1981).

• Arundel C, Lewis JH. Drug-induced liver disease in 2006. Curr. Opin. Gastroenterol. 23: 244-254 (2007).

• Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, Kontopoulos AG. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am. J. Cardiol. 80: 608-613 (1997). *

• Atkinson A, Meeks RG, Roy D. Increased oxidative stress in the liver of mice treated with trichloroethylene. Biochem. Mol. Biol. Int. 31: 297-304 (1993).

• Ayensu WK, Tchounwou PB. Microarray analysis of mercury-induced changes in gene expression in human liver carcinoma (HepG2) cells: importance in immune responses. Int. J. Environ. Res. Public Health 3: 141-173 (2006).

• Aygun C, Kocaman O, Gurbuz Y, Senturk O, Hulagu S. Clindamycin-induced acute cholestatic hepatitis. World J. Gastroenterol. 13: 5408-5410 (2007). *

• Azaz-Livshits T, Hershko A, Ben-Chetrit E. Paroxetine associated hepatotoxicity: a report of 3 cases and a review of the literature. Pharmacopsychiatry 35: 112-115 (2002).

• Bah M, Bye R, Pereda-Miranda R. Hepatotoxic pyrrolizidine alkaloids in the Mexican medicinal plant Packera candidissima (Asteraceae: Senecioneae). J. Ethnopharmacol. 43: 19-30 (1994).

• Balaji Raghavendra Rao H, Sathivel A, Devaki T. Antihepatotoxic nature of Ulva reticulata (Chlorophyceae) on acetaminophen-induced hepatoxicity in experimental rats. J. Med. Food 7: 495-497 (2004).

• Balderas-Renteria I, Camacho-Corona Mdel R, Carranza-Rosales P, Lozano-Garza HG, Castillo-Nava D, Alvarez-Mendoza FJ, Tamez-Cantu EM. Hepatoprotective effect of Leucophyllum frutescens on Wistar albino rats intoxicated with carbon tetrachloride. Ann. Hepatol. 6: 251-254 (2007). *

• Balistreri WF. Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J. Pediatr. Gastroenterol. Nutr. 24: 573-589 (1997). *

• Barnes DS. Intrahepatic cholestatic liver disease. http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm (2002). *

• Barnes S, Waldrop R, Crenshaw J, King RJ, Taylor KB. Evidence for an ordered reaction mechanism for bile salt: 3'phosphoadenosine-5'-phosphosulfate: sulfotransferase from rhesus monkey liver that catalyzes the sulfation of the hepatotoxin glycolithocholate. J. Lipid Res. 27: 1111-1123 (1986). *

• Barrio J, Castiella A, Lobo C, Indart A, Lopez P, Garcia-Bengoechea M, Cosme A, Arenas JI. Cholestatic acute hepatitis induced by amoxycillin-clavulanic acid combination. Role of ursodeoxycholic acid in drug-induced cholestasis. Rev. Esp. Enferm. Dig. 90: 523-526 (1998).

• Barton CC, Ganey PE, Roth RA. Lipopolysaccharide augments aflatoxin B(1)-induced liver injury through neutrophil-dependent and -independent mechanisms. Toxicol. Sci. 58: 208-215 (2000). *

• Barton CC, Hill DA, Yee SB, Barton EX, Ganey PE, Roth RA. Bacterial lipopolysaccharide exposure augments aflatoxin B(1)-induced liver injury. Toxicol. Sci. 55: 444-452 (2000). *

• Baskin-Bey ES, Huang W, Ishimura N, Isomoto H, Bronk SF, Braley K, Craig RW, Moore DD, Gores GJ. Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fas-induced murine liver injury by altering Bcl-2 proteins. Hepatology 44: 252-262 (2006). *

• Bastida G, Nos P, Aguas M, Beltran B, Rubin A, Dasi F, Ponce J. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 22: 775-782 (2005). *

• Battezzati PM, Podda M, Bianchi FB, Naccarato R, Orlandi F, Surrenti C, Pagliaro L, Manenti F. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC. J. Hepatol. 17: 332-338 (1993).

• Baumgardner JN, Shankar K, Korourian S, Badger TM, Ronis MJ. Undernutrition enhances alcohol-induced hepatocyte proliferation in the liver of rats fed via total enteral nutrition. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G355-G364 (2007). *

• Bazzoli F, Roda A, Fromm H, Sarva RP, Roda E, Barbara L. Relationship between serum and biliary bile acids as an indicator of chenodeoxycholic and ursodeoxycholic acid-induced hepatotoxicity in the rhesus monkey. Dig. Dis. Sci. 27: 417-424 (1982).

• Bedir A, Aliyazicioglu Y, Kahraman H, Yurdakul Z, Uysal M, Suvaci DE, Okuyucu A, Hokelek M, Alvur M. Genotoxicity in rats treated with the antidiabetic agent, rosiglitazone. Environ. Mol. Mutagen. 47: 718-724 (2006). *

• Behnam SE, Hindiyeh R, Fife DJ, Jeffes EW 3rd, Wu JJ. Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection. Clin. Exp. Dermatol. Jul 29 [Epub ahead of print] (2009). *

• Bellentani S, Tabarroni G, Barchi T, Ferretti I, Fratti N, Villa E, Manenti F. Effect of ursodeoxycholic acid treatment on alanine aminotransferase and gamma-glutamyltranspeptidase serum levels in patients with hypertransaminasemia. Results from a double-blind controlled trial. J. Hepatol. 8: 7-12 (1989).

• Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins - mechanisms and consequences. Curr. Drug Saf. 4: 209-228 (2009).

• Ben Rhouma K, Tebourbi O, Sakly M. Acute hepatotoxicity of DDT: effect on glucocorticoid receptors and serum transcortin. Indian J. Exp. Biol. 38: 452-456 (2000).

• Benninger J, Schneider HT, Schuppan D, Kirchner T, Hahn EG. Acute hepatitis induced by greater celandine (Chelidonium majus). Gastroenterology 117: 1234-1237 (1999). *

• Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am. J. Ther. 12: 133-141 (2005).

• Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J. Gen. Intern. Med. 23: 854-859 (2008). *

• Berends MA, Snoek J, DE Jong EM, VAN DE Kerkhof PC, VAN Oijen MG, VAN Krieken JH, Drenth JP. Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Aliment. Pharmacol. Ther. 24: 805-811 (2006). *

• Bergasa NV. The pruritus of cholestasis. J. Hepatol. 43: 1078-1088 (2005). *

• Bergman J, Schjott J. Hepatitis caused by Lotus-f3? Basic Clin. Pharmacol. Toxicol. 104: 414-416 (2009). *

• Berman E, Schlicht M, Moser VC, MacPhail RC. A multidisciplinary approach to toxicological screening: I. Systemic toxicity. J. Toxicol. Environ. Health 45: 127-143 (1995).

• Bernal W. Changing patterns of causation and the use of transplantation in the United Kingdom. Semin. Liver Dis. 23: 227-237 (2003).

• Bernal W, Donaldson P, Underhill J, Wendon J, Williams R. Tumor necrosis factor genomic polymorphism and outcome of acetaminophen (paracetamol)-induced acute liver failure. J. Hepatol. 29: 53-59 (1998). *

• Berson A, Freneaux E, Larrey D, Lepage V, Douay C, Mallet C, Fromenty B, Benhamou JP, Pessayre D. Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis. J. Hepatol. 20: 336-342 (1994).

• Bertolami MC. Mechanisms of hepatotoxicity. Arq. Bras. Cardiol. 85 Suppl. 4: 25-27 (2005).

• Bhadauria M, Nirala SK, Shrivastava S, Sharma A, Johri S, Chandan BK, Singh B, Saxena AK, Shukla S. Emodin reverses CCl(4) induced hepatic cytochrome P450 (CYP) enzymatic and ultrastructural changes: the in vivo evidence. Hepatol. Res. 39: 290-300 (2009). *

• Bhardwaj SS, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin. Liver Dis. 11: 597-613, vii (2007). *

• Bhat G, Jordan J Jr, Sokalski S, Bajaj V, Marshall R, Berkelhammer C. Minocycline-induced hepatitis with autoimmune features and neutropenia. J. Clin. Gastroenterol. 27: 74-75 (1998).

• Bhatia AL, Sharma A, Patni S, Sharma AL. Prophylactic effect of flaxseed oil against radiation-induced hepatotoxicity in mice. Phytother. Res. 21: 852-859 (2007). *

• Bianchi L, Terracciano LM. Giant cell hepatitis in adults. Schweiz. Rundsch. Med. Prax. 83: 1237-1241 (1994).

• Bielory L. Complementary and alternative interventions in asthma, allergy, and immunology. Ann. Allergy Asthma Immunol. 93 (2 Suppl. 1): S45-S54 (2004).

• Bjornsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J. Hepatol. 50: 511-517 (2009).

• Bjornsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J. Hepatol. 44: 791-797 (2006). *

• Black M. Drug hepatotoxicity. Clin. Liver Dis. 7: xi-xii (2003). *

• Bloomfeld RS, Onken JE. Mercaptopurine metabolite results in clinical gastroenterology practice. Aliment. Pharmacol. Ther. 17: 69-73 (2003). *

• Bock HH, Lammert F. Nuclear xeno-sensors as receptors for cholestatic bile acids: the second line of defense. Hepatology 35: 232-234 (2002). *

• Bogen KT, Gold LS. Trichloroethylene cancer risk: simplified calculation of PBPK-based MCLs for cytotoxic end points. Regul. Toxicol. Pharmacol. 25: 26-42 (1997).

• Bourdi M, Masubuchi Y, Reilly TP, Amouzadeh HR, Martin JL, George JW, Shah AG, Pohl LR. Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology 35: 289-298 (2002). *

• Bouyahia O, Boukthir S, Mrad SM, El Ghrabi AS. Diagnosis of hyper transaminasemia in childhood. Tunis. Med. 86: 722-727 (2008).

• Bove KE. Liver disease caused by disorders of bile acid synthesis. Clin. Liver Dis. 4: 831-848 (2000).

• Boyer JL. Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease? Gastroenterology 129: 735-740 (2005). *

• Bralet MP, Zafrani ES. Hepatitis caused by the amoxicillin-clavulanic acid combination. An example of drug-induced biliary hepatotoxicity. Ann. Pathol. 16: 425-429 (1996).

• Bratcher JM, Korelitz BI. Toxicity of infliximab in the course of treatment of Crohn's disease. Expert Opin. Drug Saf. 5: 9-16 (2006).

• Bratchikov OI, Lazarev AI, Siplivyi GV, Kukureka AV, Karlov PM, Siplivaia LE, Shumakova EA. Immunometabolic activity of fluoroquinolones immobilized into cell carriers in toxic lesion of the kidneys due to staphylococcal infection. Urologiia 2: 13-18 (2009).

• Brautbar N, Williams J 2nd. Industrial solvents and liver toxicity: risk assessment, risk factors and mechanisms. Int. J. Hyg. Environ. Health 205: 479-491 (2002).

• Breinig M, Caldas-Lopes E, Goeppert B, Malz M, Rieker R, Bergmann F, Schirmacher P, Mayer M, Chiosis G, Kern MA. Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology 50: 102-112 (2009).

• Brennan RJ, Schiestl RH. Chloroform and carbon tetrachloride induce intrachromosomal recombination and oxidative free radicals in Saccharomyces cerevisiae. Mutat. Res. 397: 271-278 (1998).

• Brinker AD, Wassel RT, Lyndly J, Serrano J, Avigan M, Lee WM, Seeff LB. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 49: 250-257 (2009). *

• Brown SJ, Desmond PV. Hepatotoxicity of antimicrobial agents. Semin. Liver Dis. 22: 157-167 (2002).

• Bruckner JV, Davis BD, Blancato JN. Metabolism, toxicity, and carcinogenicity of trichloroethylene. Crit. Rev. Toxicol. 20: 31-50 (1989).

• Bruckner JV, Kyle GM, Luthra R, Acosta D, Mehta SM, Sethuraman S, Muralidhara S. Acute, short-term, and subchronic oral toxicity of 1,1,1-trichloroethane in rats. Toxicol. Sci. 60: 363-372 (2001). *

• Buben JA, O'Flaherty EJ. Delineation of the role of metabolism in the hepatotoxicity of trichloroethylene and perchloroethylene: a dose-effect study. Toxicol. Appl. Pharmacol. 78: 105-122 (1985).

• Buckingham RE. Thiazolidinediones: pleiotropic drugs with potent anti-inflammatory properties for tissue protection. Hepatol. Res. 33: 167-170 (2005).

• Byrnes V, Afdhal N, Challies T, Greenstein PE. Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis. Ann. Hepatol. 5: 56-59 (2006). *

• Cadranel JF, Seddik M, Loric S, Jeanne S. Statins: hepatotoxicity and monitoring. Presse. Med. 38: 717-725 (2009).

• Cagatay T, Aydin M, Sunmez S, Cagatay P, Gulbaran Z, Gul A, Artim B, Kilicaslan Z. Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis. Rheumatol. Int. Oct 21 [Epub ahead of print] (2009). *

• Cai P, Boor PJ, Khan MF, Kaphalia BS, Ansari GA, Konig R. Immuno- and hepato-toxicity of dichloroacetic acid in MRL(+/+) and B(6)C(3)F(1) mice. J. Immunotoxicol. 4: 107-115 (2007).

• Calabuig E, Salavert M. Infectious risk. Actas Dermosifiliogr. 99 Suppl. 4: 14-22 (2008).

• Campion SN, Johnson R, Aleksunes LM, Goedken MJ, van Rooijen N, Scheffer GL, Cherrington NJ, Manautou JE. Hepatic Mrp4 induction following acetaminophen exposure is dependent on Kupffer cell function. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G294-G304 (2008). *

• Cao Q, Zhu Q, Shang Y, Gao M, Si J. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease. Digestion 79: 58-63 (2009).

• Cao Y, Colegate SM, Edgar JA. Safety assessment of food and herbal products containing hepatotoxic pyrrolizidine alkaloids: interlaboratory consistency and the importance of N-oxide determination. Phytochem. Anal. 19: 526-533 (2008). *

• Carlson GP. Effect of phenobarbital and 3-methylcholanthrene pretreatment on the hepatotoxicity of 1,1,1-trichloroethane and 1,1,2-trichloroethane. Life Sci. 13: 67-73 (1973).

• Caro AA, Cederbaum AI. Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem. Pharmacol. 69: 1081-1093 (2005). *

• Carr DF, Alfirevic A, Tugwood JD, Barratt BJ, Sherwood J, Smith J, Pirmohamed M, Kevin Park B. Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity. Pharmacogenet. Genomics 17: 961-972 (2007).

• Carrascosa MF, Lucena MI, Andrade RJ, Caviedes JR, Lavín AC, Mones JC, Rivero AP, Serrano VB. Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection. Clin. Ther. 31: 1014-1019 (2009).

• Carter BA, Karpen SJ. Intestinal failure-associated liver disease: management and treatment strategies past, present, and future. Semin. Liver Dis. 27: 251-258 (2007).

• Castell JV, Larrauri A, Gomez-Lechon MJ. A study of the relative hepatotoxicity in vitro of the non-steroidal anti-inflammatory drugs ibuprofen, flurbiprofen and butibufen. Xenobiotica 18: 737-745 (1988).

• Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 41: 690-695 (2005). *

• Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 126: 1287-1292 (2004). *

• Chalasani N, Teal E, Hall SD. Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am. J. Gastroenterol. 100: 1317-1321 (2005). *

• Chan AC, Lo CM, Ng KK, Chan SC, Fan ST. Implications for management of Mycobacterium tuberculosis infection in adult-to-adult live donor liver transplantation. Liver Int. 27: 81-85 (2007). *

• Chande N, Ponich T, Gregor J. A survey of Canadian gastroenterologists about the use of methotrexate in patients with Crohn's disease. Can. J. Gastroenterol. 19: 553-558 (2005). *

• Chapman RW. High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater? Hepatology 50: 671- 673 (2009). *

• Chapman RW. The management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 5: 9-17 (2003).

• Chawla SK, Patel HD, Parrino GR, Soterakis J, Lopresti PA, D'Angelo WA. Allopurinol hepatotoxicity. Case report and literature review. Arthritis Rheum. 20: 1546-1549 (1977).

• Chen J, Ahmad J. Cefdinir-induced hepatotoxicity: potential hazards of inappropriate antibiotic use. J. Gen. Intern. Med. 23: 1914-1916 (2008). *

• Chen J, Raymond K. Treatment effect of rifampicin on cholestasis. The Internet Journal of Pharmacology Vol. 4 (http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijpharm/vol4n2/colestasis.xml) (2006). *

• Chen LJ, Nightingale G, Baer MR. Mercaptopurine-induced fever: hypersensitivity reaction in a patient with acute lymphoblastic leukemia. Pharmacotherapy 30: 113 (2010).

• Chen P, Li C, Pang W, Zhao Y, Dong W, Wang S, Zhang J. The protective role of Per2 against carbon tetrachloride-induced hepatotoxicity. Am. J. Pathol. 174: 63-70 (2009). *

• Chen X, Zhang C, Wang H, Xu J, Duan ZH, Zhang Y, Yu T, Wei W, Xu DX, Xu JM. Altered integrity and decreased expression of hepatocyte tight junctions in rifampicin-induced cholestasis in mice. Toxicol. Appl. Pharmacol. 240: 26-36 (2009). *

• Chen Y, Wei H, Sun R, Dong Z, Zhang J, Tian Z. Increased susceptibility to liver injury in hepatitis B virus transgenic mice involves NKG2D-ligand interaction and natural killer cells. Hepatology 46: 706-715 (2007). *

• Cheng J, Ma X, Krausz KW, Idle JR, Gonzalez FJ. Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. Drug Metab. Dispos. 37: 1611-1621 (2009). *

• Cheng L, You Q, Yin H, Holt M, Franklin C, Ju C. Effect of polyI:C cotreatment on halothane-induced liver injury in mice. Hepatology 49: 215-226 (2009). *

• Cheung C, Yu AM, Ward JM, Akiyama TE, Feigenbaum L, Gonzalez FJ. The CYP2E1 humanized transgenic mouse: role of CYP2E1 acetaminophen hepatotoxicity. Drug Metab. Dispos. 33: 449-457 (2005). *

• Cheung WI, Tse ML, Ngan T, Lin J, Lee WK, Poon WT, Mak TW, Leung VK, Chau TN. Liver injury associated with the use of Fructus psoraleae (Bol-gol-zhee or Bu-gu-zhi) and its related proprietary medicine. Clin. Toxicol. (Phila.) 47: 683-685 (2009).

• Chitturi S, Farrell GC. Drug-induced liver disease. Curr. Treat. Options Gastroenterol. 3: 457-462 (2000).

• Chitturi S, Farrell GC. Hepatotoxic slimming aids and other herbal hepatotoxins. J. Gastroenterol. Hepatol. 23: 366-373 (2008). *

• Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin. Liver Dis. 22: 169-183 (2002).

• Chiu CC, Huang YT, Chuang HL, Chen HH, Chung TC. Co-exposure of lipopolysaccharide and Pseudomonas aeruginosa exotoxin A-induced multiple organ injury in rats. Immunopharmacol. Immunotoxicol. 31: 75-82 (2009).

• Cho J. Update on inflammatory bowel disease genetics. Curr. Gastroenterol. Rep. 2: 434-439 (2000).

• Choi J, Park JK, Lee KT, Park KK, Kim WB, Lee JH, Jung HJ, Park HJ. In vivo antihepatotoxic effects of Ligularia fischeri var. spiciformis and the identification of the active component, 3,4-dicaffeoylquinic acid. J. Med. Food 8: 348-352 (2005).

• Choi JH, Ahn BM, Yi J, Lee JH, Lee JH, Nam SW, Chon CY, Han KH, Ahn SH, Jang IJ, Cho JY, Suh Y, Cho MO, Lee JE, Kim KH, Lee MG. MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet. Genomics 17: 403-415 (2007).

• Chou JW, Yu CJ, Chuang PH, Lai HC, Hsu CH, Cheng KS, Peng CY, Chiang IP. Successful treatment of fosinopril-induced severe cholestatic jaundice with plasma exchange. Ann. Pharmacother. 42: 1887-1892 (2008).

• Chounta A, Zouridakis S, Ellinas C, Tsiodras S, Zoumpouli C, Kopanakis S, Giamarellou H. Cholestatic liver injury after glimepiride therapy. J. Hepatol. 42: 944-946 (2005). *

• Chow EK, Castrillo A, Shahangian A, Pei L, O'Connell RM, Modlin RL, Tontonoz P, Cheng G. A role for IRF3-dependent RXRalpha repression in hepatotoxicity associated with viral infections. J. Exp. Med. 203: 2589-2602 (2006). *

• Chowdhury A, Santra A, Bhattacharjee K, Ghatak S, Saha DR, Dhali GK. Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J. Hepatol. 45: 117-126 (2006). *

• Chuang HL, Huang YT, Chiu CC, Chen HH, Chu YY, Chen TH. Influence of age on susceptibility to Pseudomonas aeruginosa exotoxin A-induced hepatotoxicity in Long-Evans rats. J. Vet. Med. Sci. 71: 163-169 (2009). *

• Chuang JH, Wang PW, Tai MH. An adipocentric view of liver fibrosis and cirrhosis. Chang Gung Med. J. 27: 855-868 (2004).

• Cohen BI, Hofmann AF, Mosbach EH, Stenger RJ, Rothschild MA, Hagey LR, Yoon YB. Differing effects of nor-ursodeoxycholic or ursodeoxycholic acid on hepatic histology and bile acid metabolism in the rabbit. Gastroenterology 91: 189-197 (1986).

• Cohen C, Frank AL. Liver disease following occupational exposure to 1,1,1-trichloroethane: a case report. Am. J. Ind. Med. 26: 237-241 (1994).

• Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am. J. Cardiol. 97: S77-S81 (2006).

• Cohen RD. Evolving medical therapies for ulcerative colitis. Curr. Gastroenterol. Rep. 4: 497-505 (2002).

• Cohran VC, Heubi JE. Treatment of pediatric cholestatic liver disease. Curr. Treat. Options Gastroenterol. 6: 403-415 (2003).

• Coleman JD, Prabhu KS, Thompson JT, Reddy PS, Peters JM, Peterson BR, Reddy CC, Vanden Heuvel JP. The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). Free Radic. Biol. Med. 42: 1155-1164 (2007).

• Collin B, Vani A, Ogboli M, Moss C. Methotrexate treatment in 13 children with severe plaque psoriasis. Clin. Exp. Dermatol. 34: 295-298 (2009).

• Colombo C, Apostolo MG, Assaisso M, Roman B, Bottani P. Liver disease in cystic fibrosis. Neth. J. Med. 41: 119-122 (1992).

• Comcowich SA, Spitzer TR, Tsunoda SM. Ursodiol to prevent hepatic venoocclusive disease. Ann. Pharmacother. 31: 1249-1252 (1997).

• Conti E, De Checchi G, Mencarelli R, Pinato S, Rovere P. Lycopodium similiaplex-induced acute hepatitis: a case report. Eur. J. Gastroenterol. Hepatol. 20: 469-471 (2008).

• Contreras AM, Monteon FJ, Flores MR, Mendoza-Sanchez F, Ruiz I. Drug-related hepatotoxicity in a renal transplant recipient with long-term survival and hepatitis C. Ann. Hepatol. 6: 70-73 (2007). *

• Cooke A, Deshpande AV, Wong CK, Cohen R. Hepatic derangement following N-acetylcysteine enemas in an infant with cystic fibrosis. J. Paediatr. Child Health 44: 673-675 (2008).

• Cornwell PD, De Souza AT, Ulrich RG. Profiling of hepatic gene expression in rats treated with fibric acid analogs. Mutat. Res. 549: 131-145 (2004).

• Cornwell PD, Ulrich RG. Investigating the mechanistic basis for hepatic toxicity induced by an experimental chemokine receptor 5 (CCR5) antagonist using a compendium of gene expression profiles. Toxicol. Pathol. 35: 576-588 (2007). *

• Correa GH, Paredes SN. Serum liver tests in patients treated with methotrexate: a retrospective analysis. Rev. Med. Chil. 135: 1002-1008 (2007).

• Cox KL, Cox KM. Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 27: 580-583 (1998). *

• Crijns AP, de Smet PA, van den Heuvel M, Schot BW, Haagsma EB. Acute hepatitis after use of a herbal preparation with greater celandine (Chelidonium majus). Ned. Tijdschr. Geneeskd. 146: 124-128 (2002).

• Crone CC, Gabriel GM. Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations. Clin. Pharmacokinet. 43: 361-394 (2004).

• Croquet V, Fort J, Oberti F, Roquelaure Y, Ben Bouali AK, Pilette C, Cales P. 1,1,1-Trichloroethane-induced chronic active hepatitis. Gastroenterol. Clin. Biol. 27: 120-122 (2003).

• Cui YJ, Aleksunes LM, Tanaka Y, Goedken MJ, Klaassen CD. Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice. Toxicol. Sci. 110: 47-60 (2009). *

• Culley CM, Krenzelok EP. A clinical and pharmacoeconomic justification for intravenous acetylcysteine: a US perspective. Toxicol. Rev. 24: 131-143 (2005).

• Culvenor CC, Clarke M, Edgar JA, Frahn JL, Jago MV, Peterson JE, Smith LW. Structure and toxicity of the alkaloids of Russian comfrey (Symphytum x uplandicum Nyman), a medicinal herb and item of human diet. Experientia 36: 377-379 (1980).

• Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg J, Kavanaugh A, Reed G, Strand V, Kremer JM. Elevated liver enzyme tests among rheumatoid arthritis and psoriatic arthritis patients treated with methotrexate and/or leflunomide. Ann. Rheum. Dis. 69: 43-47 (2010).

• Cush JJ, Yazici Y. Laboratory monitoring of biologic therapies. Clin. Exp. Rheumatol. 23: S90-S92 (2005).

• Cvek B. TNF-alpha could be responsible for disulfiram-mediated hepatotoxicity. J. Hepatol. 49: 865-866 (2008). *

• Czaja AJ. Autoimmune hepatitis - approach to diagnosis. MedGenMed. 8: 55 (2006). *

• Daghfous R, El Aidli S, Zaiem A, Loueslati MH, Belkahia C. Sildenafil-associated hepatotoxicity. Am. J. Gastroenterol. 100: 1895-1896 (2005). *

• Dahlstrom-King L, Couture J, Lamoureux C, Vaillancourt T, Plaa GL. Dose-dependent cytotoxicity of chlorinated hydrocarbons in isolated rat hepatocytes. Fundam. Appl. Toxicol. 14: 833-841 (1990).

• Dahshan A. Prenatal exposure to methamphetamine presenting as neonatal cholestasis. J. Clin. Gastroenterol. Jul 15 [Epub ahead of print] (2008).

• Dai G, Chou N, He L, Gyamfi MA, Mendy AJ, Slitt AL, Klaassen CD, Wan YJ. RXRalpha regulates the expression of glutathione S-transferase genes and modulates acetaminophen-glutathione conjugation in mouse liver. Mol. Pharmacol. 68: 1590-1596 (2005). *

• Dai G, He L, Chou N, Wan YJ. Acetaminophen metabolism does not contribute to gender difference in its hepatotoxicity in mouse. Toxicol. Sci. 92: 33-41 (2006). *

• Dai T, Wu Y, Leng AS, Ao Y, Robel RC, Lu SC, French SW, Wan YJ. RXRalpha-regulated liver SAMe and GSH levels influence susceptibility to alcohol-induced hepatotoxicity. Exp. Mol. Pathol. 75: 194-200 (2003). *

• Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132: 272-281 (2007). *

• Dan Z, Popov Y, Patsenker E, Preimel D, Liu C, Wang XD, Seitz HK, Schuppan D, Stickel F. Hepatotoxicity of alcohol-induced polar retinol metabolites involves apoptosis via loss of mitochondrial membrane potential. FASEB J. 19: 845-847 (2005). *

• Dara L, Hewett J, Lim JK. Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements. World J. Gastroenterol. 14: 6999-7004 (2008). *

• Davern TJ 2nd. Acetaminophen hepatotoxicity. Hepatology 40: 1021-1022 (2004). *

• de Boer NK, Derijks LJ, Gilissen LP, Hommes DW, Engels LG, de-Boer SY, den Hartog G, Hooymans PM, Makelburg AB, Westerveld BD, Naber AH, Mulder CJ, de Jong DJ. On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients. World J. Gastroenterol. 11: 5540-5544 (2005). *

• de Boer NK, Mulder CJ, van Bodegraven AA. Myelotoxicity and hepatotoxicity during azathioprine therapy. Neth. J. Med. 63: 444-446 (2005). *

• de Boer NK, Reinisch W, Teml A, van Bodegraven AA, Schwab M, Lukas M, Ochsenkuhn T, Petritsch W, Knoflach P, Almer S, van der Merwe SW, Herrlinger KR, Seiderer J, Vogelsang H, Mulder CJ. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. Digestion 73: 25-31 (2006). *

• de Boer NK, van Bodegraven AA, Jharap B, de Graaf P, Mulder CJ. Drug insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat. Clin. Pract. Gastroenterol. Hepatol. 4: 686-694 (2007). *

• de Boer NK, Zondervan PE, Gilissen LP, den Hartog G, Westerveld BD, Derijks LJ, Bloemena E, Engels LG, van Bodegraven AA, Mulder CJ. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. Dig. Liver Dis. 40: 108-113 (2008).

• de Jong DJ, Derijks LJ, Naber AH, Hooymans PM, Mulder CJ. Safety of thiopurines in the treatment of inflammatory bowel disease. Scand. J. Gastroenterol. Suppl. 239: 69-72 (2003). *

• de Oliveira MR, Oliveira MW, Behr GA, de Bittencourt Pasquali MA, Moreira JC. Increased receptor for advanced glycation endproducts immunocontent in the cerebral cortex of vitamin A-treated rats. Neurochem. Res. 34: 1410-1416 (2009).

• Dejager L, Libert C. Tumor necrosis factor alpha mediates the lethal hepatotoxic effects of poly(I:C) in D-galactosamine-sensitized mice. Cytokine 42: 55-61 (2008).

• Delis S, Triantopoulou C, Bakoyiannis A, Tassopoulos N, Athanasiou K, Dervenis C. Sclerosing cholangitis in the era of target chemotherapy: a possible anti-VEGF effect. Dig. Liver Dis. 41: 72-77 (2009).

• Deng X, Stachlewitz RF, Liguori MJ, Blomme EA, Waring JF, Luyendyk JP, Maddox JF, Ganey PE, Roth RA. Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J. Pharmacol. Exp. Ther. 319: 1191-1199 (2006). *

• Deo AK, Bandiera SM. Biotransformation of lithocholic acid by rat hepatic microsomes: metabolite analysis by LC/MS. Drug Metab. Dispos. 36: 442-451 (2008). *

• Derijks LJ, de Jong DJ, Gilissen LP, Engels LG, Hooymans PM, Jansen JB, Mulder CJ. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur. J. Gastroenterol. Hepatol. 15: 63-67 (2003).

• Derijks LJ, Gilissen LP, de Boer NK, Mulder CJ. 6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent? J. Hepatol. 44: 821-822 (2006). *

• Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW. Review article: thiopurines in inflammatory bowel disease. Aliment. Pharmacol. Ther. 24: 715-729 (2006). *

• Dervieux T, Meyer G, Barham R, Matsutani M, Barry M, Boulieu R, Neri B, Seidman E. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy. Clin. Chem. 51: 2074-2084 (2005). *

• Desanty KP, Amabile CM. Antidepressant-induced liver injury. Ann. Pharmacother. 41: 1201-1211 (2007).

• Deshpande SS, Lalitha VS, Ingle AD, Raste AS, Gadre SG, Maru GB. Subchronic oral toxicity of turmeric and ethanolic turmeric extract in female mice and rats. Toxicol. Lett. 95: 183-193 (1998).

• Dew MJ, van Berge Henegouwen GP, Huybregts AW, Allan RN. Hepatotoxic effect of bile acids in inflammatory bowel disease. Gastroenterology 78: 1393-1401 (1980).

• Dharancy S, Lemoine M, Mathurin P, Serfaty L, Dubuquoy L. Peroxisome proliferator-activated receptors in HCV-related infection. PPAR Res. 2009: 357204 (2009). *

• Diaz FJ, Davalos MM, Roman VR, Bustios SC, Zumaeta VE. Hepatotoxicity and pancreatitis associated with gold salts: case report. Rev. Gastroenterol. Peru 24: 353-356 (2004).

• Diehl AM. Role of the immune system in the pathogenesis of nonalcoholic steatohepatitis. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 78 (2005). *

• Diehl AM. Alcoholic liver disease. Clin. Liver Dis. 2: 103-118 (1998).

• Domenech E, Manosa M, Navarro M, Masnou H, Garcia-Planella E, Zabana Y, Cabre E, Gassull MA. Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice. J. Clin. Gastroenterol. 42: 395-399 (2008).

• Donthamsetty S, Bhave VS, Mitra MS, Latendresse JR, Mehendale HM. Nonalcoholic steatohepatitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPARalpha with clofibrate. Toxicol. Appl. Pharmacol. 230: 327-337 (2008). *

• Dourakis SP, Papanikolaou IS, Tzemanakis EN, Hadziyannis SJ. Acute hepatitis associated with herb (Teucrium capitatum L.) administration. Eur. J. Gastroenterol. Hepatol. 14: 693-695 (2002).

• Dubinsky MC. Optimizing immunomodulator therapy for inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 506-511 (2003).

• Dubinsky MC, Fleshner PP. Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes. Curr. Treat. Options Gastroenterol. 6: 183-200 (2003).

• Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118: 705-713 (2000). *

• Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122: 904-915 (2002). *

• Durazo FA, Lassman C, Han SH, Saab S, Lee NP, Kawano M, Saggi B, Gordon S, Farmer DG, Yersiz H, Goldstein RL, Ghobrial M, Busuttil RW. Fulminant liver failure due to usnic acid for weight loss. Am. J. Gastroenterol. 99: 950-952 (2004). *

• Eastin CE, McClain CJ, Lee EY, Bagby GJ, Chawla RK. Choline deficiency augments and antibody to tumor necrosis factor-alpha attenuates endotoxin-induced hepatic injury. Alcohol Clin. Exp. Res. 21: 1037-1041 (1997). *

• Echard BW, Talpur NA, Fan AY, Bagchi D, Preuss HG. Hepatoprotective ability of a novel botanical formulation on mild liver injury in rats produced by acute acetaminophen and/or alcohol ingestion. Res. Commun. Mol. Pathol. Pharmacol. 110: 73-85 (2001).

• Ehmsen L, Marko C, Breidert M. Portal vein hypertension with azathioprine therapy in patients with Crohn's disease - is it a frequent phenomenon? Dtsch. Med. Wochenschr. 133: 950-953 (2008).

• Ehrmann J, Strojil J. Current concepts and morphological aspects of drug induced liver injury. Cesk. Patol. 44: 4-7 (2008).

• Eipel C, Eisold M, Schuett H, Vollmar B. Inhibition of heme oxygenase-1 protects against tissue injury in carbon tetrachloride exposed livers. J. Surg. Res. 139: 113-120 (2007). *

• Ekam VS, Ebong PE. Serum protein and enzyme levels in rats following administration of antioxidant vitamins during caffeinated and non-caffeinated paracetamol induced hepatotoxicity. Niger. J. Physiol. Sci. 22: 65-68 (2007).

• El-Sherbiny GA, Taye A, Abdel-Raheem IT. Role of ursodeoxycholic acid in prevention of hepatotoxicity caused by amoxicillin-clavulanic acid in rats. Ann. Hepatol. 8: 134-140 (2009). *

• Elbek O, Uyar M, Aydin N, Borekci S, Bayram N, Bayram H, Dikensoy O. Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha. Clin. Rheumatol. 28: 421-426 (2009). *

• Elefsiniotis IS, Liatsos GD, Stamelakis D, Moulakakis A. Case report: mixed cholestatic/hepatocellular liver injury induced by the herbicide quizalofop-p-ethyl. Environ. Health Perspect. 115: 1479-1481 (2007). *

• Elekima OT, Mills CO, Ahmad A, Skinner GR, Ramsden DB, Bown J, Young TW, Elias E. Reduced hepatic content of dehydroepiandrosterone sulphotransferase in chronic liver diseases. Liver 20: 45-50 (2000). *

• Elinav E, Pinsker G, Safadi R, Pappo O, Bromberg M, Anis E, Keinan-Boker L, Broide E, Ackerman Z, Kaluski DN, Lev B, Shouval D. Association between consumption of Herbalife((R)) nutritional supplements and acute hepatotoxicity. J. Hepatol. 47: 514-520 (2007). *

• Elisa Bohmer A, Ribeiro Correa AM, de Souza DG, Knorr L, Hansel G, Gustavo Corbellini L, Driemeier D, Valmor Portela L, Onofre Souza D. Long-term cyclosporine treatment: evaluation of serum biochemical parameters and histopathological alterations in Wistar rats. Exp. Toxicol. Pathol. Nov 23 [Epub ahead of print] (2009). *

• Enomoto M, Sakaguchi H, Ominami M, Iwai S, Morikawa H, Tamori A, Kawada N. Sildenafil-induced severe cholestatic hepatotoxicity. Am. J. Gastroenterol. 104: 254-255 (2009). *

• Enomoto N, Takei Y, Kon K, Yamashina S, Suzuki S, Ikejima K, Sato N. Serine protease inhibitors prevent alcoholic liver injury. Nihon Arukoru Yakubutsu Igakkai Zasshi 40: 213-218 (2005).

• Epstein O, Arborgh B, Sagiv M, Wroblewski R, Scheuer PJ, Sherlock S. Is copper hepatotoxic in primary biliary cirrhosis? J. Clin. Pathol. 34: 1071-1075 (1981). *

• Estes JD, Stolpman D, Olyaei A, Corless CL, Ham JM, Schwartz JM, Orloff SL. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch. Surg. 138: 852-858 (2003). *

• Everson GT, Ahnen D, Harper PC, Krawitt EL. Benign recurrent intrahepatic cholestasis: treatment with S-adenosylmethionine. Gastroenterology 96: 1354-1357 (1989).

• Fairley CK, McNeil JJ, Desmond P, Smallwood R, Young H, Forbes A, Purcell P, Boyd I. Risk factors for development of flucloxacillin associated jaundice. BMJ 306: 233-235 (1993). *

• Fallon MB, Boyer JL. Hepatic toxicity of vitamin A and synthetic retinoids. J. Gastroenterol. Hepatol. 5: 334-342 (1990).

• Fannin RD, Russo M, O'Connell TM, Gerrish K, Winnike JH, Macdonald J, Newton J, Malik S, Sieber SO, Parker J, Shah R, Zhou T, Watkins PB, Paules RS. Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation. Hepatology 51: 227-236 (2010).

• Fargion S, Valenti L, Dongiovanni P, Scaccabarozzi A, Fracanzani AL, Taioli E, Mattioli M, Sampietro M, Fiorelli G. Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood 97: 3707-3712 (2001). *

• Farinati F, De Bona M, Floreani A, Foschia F, Rugge M. Helicobacter pylori and the liver: any relationship? Ital. J. Gastroenterol. Hepatol. 30: 124-128 (1998).

• Farkas D, Tannenbaum SR. In vitro methods to study chemically-induced hepatotoxicity: a literature review. Curr. Drug Metab. 6: 111-125 (2005).

• Farmer JA, Gotto AM Jr. Currently available hypolipidaemic drugs and future therapeutic developments. Baillieres Clin. Endocrinol. Metab. 9: 825-847 (1995).

• Farrell GC. Drug-induced hepatic injury. J. Gastroenterol. Hepatol. 12: S242-S250 (1997).

• Farrell GC. Drugs and steatohepatitis. Semin. Liver Dis. 22: 185-194 (2002).

• Farrell GC, Duddy SK, Kass GE, Llopis J, Gahm A, Orrenius S. Release of Ca2+ from the endoplasmic reticulum is not the mechanism for bile acid-induced cholestasis and hepatotoxicity in the intact rat liver. J. Clin. Invest. 85: 1255-1259 (1990). *

• Farver DK, Lavin MN. Quinine-induced hepatotoxicity. Ann. Pharmacother. 33: 32-34 (1999).

• Feldman PA, Regev A, Barkin JS. Hepatobiliary disorders associated with inflammatory bowel disease. Practical Gastroenterology, August 2006: 52-74 (2006). *

• Feng B, Xu JJ, Bi YA, Mireles R, Davidson R, Duignan DB, Campbell S, Kostrubsky VE, Dunn MC, Smith AR, Wang HF. Role of hepatic transporters in the disposition and hepatotoxicity of a Her2 tyrosine kinase inhibitor CP-724,714. Toxicol. Sci. 108: 492-500 (2009). *

• Fennerty MB. Primary sclerosing cholangitis and primary biliary cirrhosis. How effective is medical therapy? Postgrad. Med. 94: 81-88 (1993).

• Fernandes NF, Geller SA, Fong TL. Terbinafine hepatotoxicity: case report and review of the literature. Am. J. Gastroenterol. 93: 459-460 (1998).

• Fernandes NF, Martin RR, Schenker S. Trazodone-induced hepatotoxicity: a case report with comments on drug-induced hepatotoxicity. Am. J. Gastroenterol. 95: 532-535 (2000). *

• Fernandez-Martinez A, Callejas NA, Casado M, Bosca L, Martin-Sanz P. Thioacetamide-induced liver regeneration involves the expression of cyclooxygenase 2 and nitric oxide synthase 2 in hepatocytes. J. Hepatol. 40: 963-970 (2004). *

• Feuer G, Di Fonzo CJ. Intrahepatic cholestasis: a review of biochemical-pathological mechanisms. Drug Metabol. Drug Interact. 10: 1-161 (1992).

• Fiorucci S, Antonelli E, Distrutti E, Mencarelli A, Farneti S, Soldato PD, Morelli A. Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice. Br. J. Pharmacol. 143: 33-42 (2004). *

• Fletcher N, Wahlstrom D, Lundberg R, Nilsson CB, Nilsson KC, Stockling K, Hellmold H, Hakansson H. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) alters the mRNA expression of critical genes associated with cholesterol metabolism, bile acid biosynthesis, and bile transport in rat liver: a microarray study. Toxicol. Appl. Pharmacol. 207: 1-24 (2005). *

• Fogden E, Neuberger J. Alternative medicines and the liver. Liver Int. 23: 213-220 (2003). *

• Fong DG, Angulo P, Burgart LJ, Lindor KD. Cetirizine-induced cholestasis. J. Clin. Gastroenterol. 31: 250-253 (2000).

• Fong TL, Klontz KC, Canas-Coto A, Casper SJ, Durazo FA, Davern TJ 2nd, Hayashi P, Lee WM, Seeff LB. Hepatotoxicity due to hydroxycut: a case series. Am. J. Gastroenterol. Jan 26 [Epub ahead of print] (2010). *

• Fonseca JE, Reis P, Saraiva F, Crujo C, Baptista A, da Silva JA, Viana Queiroz M. A complex case of hepatitis in a patient with systemic lupus erythematosus. Clin. Rheumatol. 18: 414-416 (1999).

• Fontana RJ, Shakil AO, Greenson JK, Boyd I, Lee WM. Acute liver failure due to amoxicillin and amoxicillin/clavulanate. Dig. Dis. Sci. 50: 1785-1790 (2005). *

• Forbes GM, Jeffrey GP, Shilkin KB, Reed WD. Carbamazepine hepatotoxicity: another cause of the vanishing bile duct syndrome. Gastroenterology 102: 1385-1388 (1992).

• Ford TJ, Dillon JF. Minocycline hepatitis. Eur. J. Gastroenterol. Hepatol. 20: 796-799 (2008).

• Foreman JE, Chang SC, Ehresman DJ, Butenhoff JL, Anderson CR, Palkar PS, Kang BH, Gonzalez FJ, Peters JM. Differential hepatic effects of perfluorobutyrate (PFBA) mediated by mouse and human PPARalpha. Toxicol. Sci. 110: 204-211 (2009). *

• Fournier MR, Klein J, Minuk GY, Bernstein CN. Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. Am. J. Gastroenterol. Feb 16 [Epub ahead of print] (2010). *

• Fowler R, Imrie K. Thalidomide-associated hepatitis: a case report. Am. J. Hematol. 66: 300-302 (2001).

• Franco J, Saeian K. Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis. Curr. Gastroenterol. Rep. 1: 95-101 (1999).

• Frankel AJ, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF Jr, Gottlieb AB; for the National Psoriasis Foundation. Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J. Am. Acad. Dermatol. 61: 1044-1055 (2009).

• Friedel HA, Goa KL, Benfield P. S-Adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 38: 389-416 (1989).

• Fulford A, Scolapio JS, Aranda-Michel J. Parenteral nutrition-associated hepatotoxicity. Nutr. Clin. Pract. 19: 274-283 (2004). *

• Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol. 59: 627-635 (2001). *

• Gabele E, Froh M, Arteel GE, Uesugi T, Hellerbrand C, Scholmerich J, Brenner DA, Thurman RG, Rippe RA. TNFalpha is required for cholestasis-induced liver fibrosis in the mouse. Biochem. Biophys. Res. Commun. 378: 348-353 (2009). *

• Gabolde M, Hubert D, Guilloud-Bataille M, Lenaerts C, Feingold J, Besmond C. The mannose binding lectin gene influences the severity of chronic liver disease in cystic fibrosis. J. Med. Genet. 38: 310-311 (2001). *

• Galan AI, Munoz ME, Jimenez R. S-Adenosylmethionine protects against cyclosporin A-induced alterations in rat liver plasma membrane fluidity and functions. J. Pharmacol. Exp. Ther. 290: 774-781 (1999). *

• Galle PR, Theilmann L, Raedsch R, Otto G, Stiehl A. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology 12: 486-491 (1990).

• Gao S, Gui XE, Deng L, Zhang Y, Liang K, Yang R, Yan Y, Rong Y. Antiretroviral therapy hepatotoxicity: prevalence, risk factors, and clinical characteristics in a cohort of Han Chinese. Hepatol. Res. Jan 11 [Epub ahead of print] (2010). *

• Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J. Gastroenterol. 15: 280-288 (2009). *

• Garcia-Compean D, Jaquez-Quintana JO, Maldonado-Garza H. Hepatogenous diabetes. Current views of an ancient problem. Ann. Hepatol. 8: 13-20 (2009). *

• Gardner CR, Heck DE, Yang CS, Thomas PE, Zhang XJ, DeGeorge GL, Laskin JD, Laskin DL. Role of nitric oxide in acetaminophen-induced hepatotoxicity in the rat. Hepatology 27: 748-754 (1998). *

• Garg A, Simha V. Update on dyslipidemia. J. Clin. Endocrinol. Metab. 92: 1581-1589 (2007). *

• Garnica AD. The hepatotoxicity of parenteral protein hydrolysate-containing solutions. Ann. Clin. Lab. Sci. 6: 446-454 (1976).

• Gartung C, Ananthanarayanan M, Rahman MA, Schuele S, Nundy S, Soroka CJ, Stolz A, Suchy FJ, Boyer JL. Down-regulation of expression and function of the rat liver Na+/bile acid cotransporter in extrahepatic cholestasis. Gastroenterology 110: 199-209 (1996). *

• Geller SA, Dubinsky MC, Poordad FF, Vasiliauskas EA, Cohen AH, Abreu MT, Tran T, Martin P, Vierling JM, Targan SR. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am. J. Surg. Pathol. 28: 1204-1211 (2004).

• Gerloff T, Geier A, Stieger B, Hagenbuch B, Meier PJ, Matern S, Gartung C. Differential expression of basolateral and canalicular organic anion transporters during regeneration of rat liver. Gastroenterology 117: 1408-1415 (1999). *

• Ghali P, Lindor KD. Hepatotoxicity of drugs used for treatment of obesity and its comorbidities. Semin. Liver Dis. 24: 389-397 (2004).

• Giannandrea M, Pierce RH, Crispe IN. Indirect action of tumor necrosis factor-alpha in liver injury during the CD8+ T cell response to an adeno-associated virus vector in mice. Hepatology 49: 2010-2020 (2009).

• Giannattasio A, D'Ambrosi M, Volpicelli M, Iorio R. Steroid therapy for a case of severe drug-induced cholestasis. Ann. Pharmacother. 40: 1196-1199 (2006).

• Gigliozzi A, Romeo R, Fraioli F, Cantafora A, Delle Monache M, Cardilli A, Attili AF, Scafato E, Carli L, Alvaro D. Effect of S-adenosyl-L-methionine and dilinoleoylphosphatidylcholine on liver lipid composition and ethanol hepatotoxicity in isolated perfused rat liver. Dig. Dis. Sci. 43: 2211-2222 (1998). *

• Gilissen LP, Bierau J, Derijks LJ, Bos LP, Hooymans PM, Gennip A, Stockbrugger RW, Engels LG. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment. Pharmacol. Ther. 22: 605-611 (2005). *

• Gilissen LP, Derijks LJ, Bos LP, Bus PJ, Hooymans PM, Engels LG. Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy. Clin. Drug Investig. 24: 479-486 (2004).

• Gilissen LP, Derijks LJ, Driessen A, Bos LP, Hooymans PM, Stockbrugger RW, Engels LG. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects? Dig. Liver Dis. 39: 156-159 (2007).

• Girlanda R, Vilca-Melendez H, Srinivasan P, Muiesan P, O'Grady JG, Rela M, Heaton ND. Immunosuppression withdrawal after auxiliary liver transplantation for acute liver failure. Transplant. Proc. 37: 1720-1721 (2005). *

• Gisbert JP, Gonzalez-Lama Y, Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am. J. Gastroenterol. 102: 1518-1527 (2007). *

• Gisbert JP, Luna M, Gonzalez-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, Mate J. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm. Bowel Dis. 13: 1106-1114 (2007). *

• Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am. J. Gastroenterol. 99: 1744-1748 (2004). *

• Gomollon F, Garcia Lopez S. Are we giving azathioprine too much time? World J. Gastroenterol. 14: 5519-5522 (2008). *

• Gonzalez U, Reyes E, Kershenovich J, Orozco-Topete RL. Hypersensitivity syndrome caused by allopurinol. A case of massive hepatic necrosis. Rev. Invest. Clin. 47: 409-413 (1995).

• Gotto AM Jr. Risks and benefits of continued aggressive statin therapy. Clin. Cardiol. 26: III3-III12 (2003).

• Graf D, Kohlmann C, Haselow K, Gehrmann T, Bode JG, Haussinger D. Bile acids inhibit interleukin-6 signaling via gp130 receptor-dependent and -independent pathways in rat liver. Hepatology 44: 1206-1217 (2006). *

• Graham RC, Burke A, Stettler N. Ethnic and sex differences in the association between metabolic syndrome and suspected nonalcoholic fatty liver disease in a nationally representative sample of US adolescents. J. Pediatr. Gastroenterol. Nutr. Jul 28 [Epub ahead of print] (2009).

• Grattagliano I, Bonfrate L, Diogo CV, Wang HH, Wang DQ, Portincasa P. Biochemical mechanisms in drug-induced liver injury: certainties and doubts. World J. Gastroenterol. 15: 4865-4876 (2009). *

• Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Overview on the mechanisms of drug-induced liver cell death. Ann. Hepatol. 1: 162-168 (2002). *

• Grieco A, Forgione A, Miele L, Vero V, Greco AV, Gasbarrini A, Gasbarrini G. Fatty liver and drugs. Eur. Rev. Med. Pharmacol. Sci. 9: 261-263 (2005).

• Grieco A, Miele L, Pompili M, Biolato M, Vecchio FM, Grattagliano I, Gasbarrini G. Acute hepatitis caused by a natural lipid-lowering product: when “alternative” medicine is no “alternative” at all? J. Hepatol. 50: 1273-1277 (2009).

• Griffin JM, Gilbert KM, Pumford NR. Inhibition of CYP2E1 reverses CD4+ T-cell alterations in trichloroethylene-treated MRL+/+ mice. Toxicol. Sci. 54: 384-389 (2000). *

• Grismer LE, Gill SA, Harris MD. Liver biopsy in psoriatic arthritis to detect methotrexate hepatotoxicity. J. Clin. Rheumatol. 7: 224-227 (2001).

• Grogan PM, Katz JS. Inflammatory myopathies. Curr. Treat. Options Neurol. 6: 155-161 (2004).

• Groneberg DA, Grosse-Siestrup C, Fischer A. In vitro models to study hepatotoxicity. Toxicol. Pathol. 30: 394-399 (2002). *

• Grover JK, Yadav S, Vats V, Joshi YK. Cyclo-oxygenase 2 inhibitors: emerging roles in the gut. Int. J. Colorectal Dis. 18: 279-291 (2003). *

• Grunhage F, Fischer HP, Sauerbruch T, Reichel C. Drug- and toxin-induced hepatotoxicity. Z. Gastroenterol. 41: 565-578 (2003).

• Guler R, Olleros ML, Vesin D, Parapanov R, Vesin C, Kantengwa S, Rubbia-Brandt L, Mensi N, Angelillo-Scherrer A, Martinez-Soria E, Tacchini-Cottier F, Garcia I. Inhibition of inducible nitric oxide synthase protects against liver injury induced by mycobacterial infection and endotoxins. J. Hepatol. 41: 773-781 (2004). *

• Gumpricht E, Dahl R, Devereaux MW, Sokol RJ. Licorice compounds, glycyrrhizin and 18beta -glycyrrhetinic acid, are potent modulators of bile acid-induced cytotoxicity in rat hepatocytes. J. Biol. Chem. 280: 10556-10563 (2005). *

• Gumpricht E, Dahl R, Devereaux MW, Sokol RJ. Beta-carotene prevents bile acid-induced cytotoxicity in the rat hepatocyte: evidence for an antioxidant and anti-apoptotic role of beta-carotene in vitro. Pediatr. Res. 55: 814-821 (2004). *

• Gunawan B, Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab. Rev. 36: 301-312 (2004). *

• Gunawan BK, Liu ZX, Han D, Hanawa N, Gaarde WA, Kaplowitz N. c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology 131: 165-178 (2006). *

• Gundala S, Wells LD, Milliano MT, Talkad V, Luxon BA, Neuschwander-Tetri BA. The hepatocellular bile acid transporter Ntcp facilitates uptake of the lethal mushroom toxin alpha-amanitin. Arch. Toxicol. 78: 68-73 (2004). *

• Gundling F, Rohrbach H, Schepp W. Cholestatic hepatitis in situs inversus abdominalis. Schweiz. Rundsch. Med. Prax. 96: 1029-1033 (2007).

• Gundling F, Tillmann HL, Schmidt O, Brennenstuhl M, Nerlich A, Schepp W. Severe intrahepatic cholestasis in a 66-year old male with atrial fibrillation recieving antiarryhthmic drug-therapy. Internist (Berl.) 46: 1038-1042 (2005).

• Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, Urabe A. Light and moderate alcohol consumption significantly reduces the prevalence of fatty liver in the Japanese male population. Am. J. Gastroenterol. 104: 2189-2195 (2009).

• Guo D, Sarkar J, Ahmed MR, Viswakarma N, Jia Y, Yu S, Sambasiva Rao M, Reddy JK. Peroxisome proliferator-activated receptor (PPAR)-binding protein (PBP) but not PPAR-interacting protein (PRIP) is required for nuclear translocation of constitutive androstane receptor in mouse liver. Biochem. Biophys. Res. Commun. 347: 485-495 (2006). *

• Guo GL, Moffit J, Nicol CJ, Ward JM, Aleksunes L, Slitt A, Kliewer SA, Manautou J, Gonzalez FJ. Enhanced acetaminophen toxicity by activation of the pregnane X receptor. Toxicol. Sci. 82: 374-380 (2004). *

• Guo L, Zhang L, Sun Y, Muskhelishvili L, Blann E, Dial S, Shi L, Schroth G, Dragan YP. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Mol. Divers. 10: 349-360 (2006).

• Gustafsson J, Alvelius G, Bjorkhem I, Nemeth A. Bile acid metabolism in extrahepatic biliary atresia: lithocholic acid in stored dried blood collected at neonatal screening. Ups. J. Med. Sci. 111: 131-136 (2006). *

• Gut J, Christen U, Frey N, Koch V, Stoffler D. Molecular mimicry in halothane hepatitis: biochemical and structural characterization of lipoylated autoantigens. Toxicology 97: 199-224 (1995).

• Gut J, Christen U, Huwyler J. Mechanisms of halothane toxicity: novel insights. Pharmacol. Ther. 58: 133-155 (1993).

• Gyamfi MA, Damjanov I, French S, Wan YJ. The pathogenesis of ethanol versus methionine and choline deficient diet-induced liver injury. Biochem. Pharmacol. 75: 981-995 (2008). *

• Haarmann-Stemmann T, Bothe H, Abel J. Growth factors, cytokines and their receptors as downstream targets of arylhydrocarbon receptor (AhR) signaling pathways. Biochem. Pharmacol. 77: 508-520 (2009). *

• Hanasono GK, Witschi H, Plaa GL. Potentiation of the hepatotoxic responses to chemicals in alloxan-diabetic rats. Proc. Soc. Exp. Biol. Med. 149: 903-907 (1975).

• Hanauer SB. New biologicals for inflammatory bowel disease. Gastroenterology & Hepatology Annual Review Vol. 1, June 2006, p. 67-71 (2006). *

• Hanje AJ, Shamp JL, Thomas FB, Meis GM. Thalidomide-induced severe hepatotoxicity. Pharmacotherapy 26: 1018-1022 (2006). *

• Hanta I, Ozbek S, Kuleci S, Sert M, Kocabas A. Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha. Clin. Rheumatol. 26: 1867-1870 (2007). *

• Harper N, Macfarlane M. Chapter 18. Recombinant TRAIL and TRAIL receptor analysis. Methods Enzymol. 446C: 293-313 (2008).

• Harputluoglu MM, Demirel U, Karadag N, Karahan D, Aladag M, Karincaoglu M, Hilmioglu F. Severe hepatitis with prolonged cholestasis and bile duct injury due the long-term use of ornidazole. Acta Gastroenterol. Belg. 70: 293-295 (2007).

• Hartleb M, Biernat L, Kochel A. Drug-induced liver damage - a three-year study of patients from one gastroenterological department. Med. Sci. Monit. 8: CR292-CR296 (2002). *

• Hasan F. Isoflurane hepatotoxicity in a patient with a previous history of halothane-induced hepatitis. Hepatogastroenterology 45: 518-522 (1998).

• Hasegawa M, Ide M, Fujita T, Takenaka S. Urinary metabolic fingerprinting for alpha-naphthylisothiocyanate-induced intrahepatic cholestasis in rats using Fourier transform-ion cyclotron resonance mass spectrometry. Toxicol. Pathol. 36: 818-826 (2008). *

• Hasselblatt P, Rath M, Komnenovic V, Zatloukal K, Wagner EF. Hepatocyte survival in acute hepatitis is due to c-Jun/AP-1-dependent expression of inducible nitric oxide synthase. Proc. Natl. Acad. Sci. U.S.A. 104: 17105-17110 (2007). *

• Hautekeete ML. Hepatotoxicity of antibiotics. Acta Gastroenterol. Belg. 58: 290-296 (1995).

• Hautekeete ML, Henrion J, Naegels S, DeNeve A, Adler M, Deprez C, Devis G, Kloppel G. Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities. Liver 15: 25-29 (1995).

• Hawton K, Simkin S, Deeks J, Cooper J, Johnston A, Waters K, Arundel M, Bernal W, Gunson B, Hudson M, Suri D, Simpson K. UK legislation on analgesic packs: before and after study of long term effect on poisonings. BMJ 329: 1076 (2004). *

• Hayashi H, Sugiyama Y. Short-chain ubiquitination is associated with the degradation rate of a cell-surface-resident bile salt export pump (BSEP/ABCB11). Mol. Pharmacol. 75: 143-150 (2009). *

• Haywood S, Muller T, Mackenzie AM, Muller W, Tanner MS, Heinz-Erian P, Williams CL, Loughran MJ. Copper-induced hepatotoxicosis with hepatic stellate cell activation and severe fibrosis in North Ronaldsay lambs: a model for non-Wilsonian hepatic copper toxicosis of infants. J. Comp. Pathol. 130: 266-277 (2004). *

• Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Michieletti P, Minuk GY, Pappas SC, Scully LJ, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 19: 1149-1156 (1994).

• Heathcote J, Wanless IR. Hepatotoxicity: newer aspects of pathogenesis and treatment. Gastroenterologist 3: 119-129 (1995).

• Helliwell PS, Taylor WJ. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs - comparison of drugs and adverse reactions. J. Rheumatol. 35: 472-476 (2008).

• Helmchen C, Boerner RJ, Meyendorf R, Hegerl U. Reversible hepatotoxicity of paroxetine in a patient with major depression. Pharmacopsychiatry 29: 223-226 (1996).

• Henderson NC, Pollock K, Frew J, Mackinnon AC, Flavell RA, Davis RJ, Sethi T, Simpson KJ. Critical role of c-jun (NH2) terminal kinase in paracetamol-induced acute liver failure. Gut 56: 982-990 (2007). *

• Henriquez-Hernandez LA, Flores-Morales A, Santana-Farre R, Axelson M, Nilsson P, Norstedt G, Fernandez-Perez L. Role of pituitary hormones on 17alpha-ethinylestradiol-induced cholestasis in rat. J. Pharmacol. Exp. Ther. 320: 695-705 (2007). *

• Herraez E, Macias RI, Vazquez-Tato J, Hierro C, Monte MJ, Marin JJ. Protective effect of bile acid derivatives in phalloidin-induced rat liver toxicity. Toxicol. Appl. Pharmacol. 239: 21-28 (2009). *

• Herrera S, Bruguera M. Hepatotoxicity induced by herbs and medicines used to induce weight loss. Gastroenterol. Hepatol. 31: 447-453 (2008).

• Herrine SK. Drug-induced liver disease. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).

• Herrlinger KR, Deibert P, Schwab M, Kreisel W, Fischer C, Fellermann K, Stange EF. Remission maintenance by tioguanine in chronic active Crohn's disease. Aliment. Pharmacol. Ther. 17: 1459-1464 (2003). *

• Higgins PD, Fontana RJ. Liver transplantation in acute liver failure. Panminerva. Med. 45: 85-94 (2003).

• Higuchi H, Gores GJ. Mechanisms of liver injury: an overview. Curr. Mol. Med. 3: 483-490 (2003).

• Higuchi N, Tahara N, Yanagihara K, Fukushima K, Suyama N, Inoue Y, Miyazaki Y, Kobayashi T, Yoshiura K, Niikawa N, Wen CY, Isomoto H, Shikuwa S, Omagari K, Mizuta Y, Kohno S, Tsukamoto K. NAT2*6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J. Gastroenterol. 13: 6003-6008 (2007). *

• Hindorf U, Johansson M, Eriksson A, Kvifors E, Almer SH. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 29: 654-661 (2009). *

• Hinson JA, Reid AB, McCullough SS, James LP. Acetaminophen-induced hepatotoxicity: role of metabolic activation, reactive oxygen/nitrogen species, and mitochondrial permeability transition. Drug Metab. Rev. 36: 805-822 (2004).

• Hodgson MJ, Heyl AE, Van Thiel DH. Liver disease associated with exposure to 1,1,1-trichloroethane. Arch. Intern. Med. 149: 1793-1798 (1989).

• Hofmann AF. Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity. Drug Metab. Rev. 36: 703-722 (2004).

• Hofmann AF. Biliary secretion and excretion in health and disease: current concepts. Ann. Hepatol. 6: 15-27 (2007). *

• Hofmann AF, Schteingart CD, Lillienau J. Biological and medical aspects of active ileal transport of bile acids. Ann. Med. 23: 169-175 (1991).

• Holt MP, Ju C. Mechanisms of drug-induced liver injury. AAPS J. 8: E48-E54 (2006). *

• Honma T. Effects of trichloroethylene, 1,1,1-trichloroethane and carbon tetrachloride on plasma lipoproteins of rats. Ind. Health 28: 159-174 (1990).

• Howard PJ, Murphy GM. Bile acid stress in the mother and baby unit. Eur. J. Gastroenterol. Hepatol. 15: 317-321 (2003).

• Howarth DL, Law SH, Law JM, Mondon JA, Kullman SW, Hinton DE. Exposure to the synthetic FXR agonist GW4064 causes alterations in gene expression and sublethal hepatotoxicity in eleutheroembryo medaka (Oryzias latipes). Toxicol. Appl. Pharmacol. 31: 80-86 (2010). *

• Huang L, Heinloth AN, Zeng ZB, Paules RS, Bushel PR. Genes related to apoptosis predict necrosis of the liver as a phenotype observed in rats exposed to a compendium of hepatotoxicants. BMC Genomics 9: 288 (2008). *

• Huang LJ, Zhu Q, Lei M, Cao Q. Current use of immunosuppressive agents in inflammatory bowel disease patients in East China. World J. Gastroenterol. 15: 3055-3059 (2009). *

• Huang MJ, Liaw YF. Clinical associations between thyroid and liver diseases. J. Gastroenterol. Hepatol. 10: 344-350 (1995).

• Huang X, Shao L, Gong Y, Mao Y, Liu C, Qu H, Cheng Y. A metabonomic characterization of CCl(4)-induced acute liver failure using partial least square regression based on the GC/MS metabolic profiles of plasma in mice. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 870: 178-185 (2008). *

• Huang YS, Su WJ, Huang YH, Chen CY, Chang FY, Lin HC, Lee SD. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J. Hepatol. 47: 128-134 (2007). *

• Hull K, Horenstein R, Naglieri R, Munir K, Ghany M, Celi FS. Two cases of thyroid storm-associated cholestatic jaundice. Endocr. Pract. 13: 476-480 (2007).

• Hultin-Rosenberg L, Jagannathan S, Nilsson KC, Matis SA, Sjogren N, Huby RD, Salter AH, Tugwood JD. Predictive models of hepatotoxicity using gene expression data from primary rat hepatocytes. Xenobiotica 36: 1122-1139 (2006). *

• Humayun F, Shehab TM, Tworek JA, Fontana RJ. A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: a case report. J. Med. Case Reports 1: 88 (2007). *

• Hundsberger H, Verin A, Wiesner C, Pfluger M, Dulebo A, Schutt W, Lasters I, Mannel DN, Wendel A, Lucas R. TNF: a moonlighting protein at the interface between cancer and infection. Front. Biosci. 13: 5374-5386 (2008).

• Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin. Drug Saf. 6: 673-684 (2007).

• Hwang J. Diets with corn oil and/or low protein increase acute acetaminophen hepatotoxicity compared to diets with beef tallow in a rat model. Nutr. Res. Pract. 3: 95-101 (2009).

• Hydzik P, Drozdz M, Sulowicz W, Groszek B. Liver albumin dialysis - application in acetaminophen poisoning. Przegl. Lek. 61: 377-382 (2004).

• Ierardi E, Della Valle N, Cosimo Nacchiero M, De Francesco V, Stoppino G, Panella C. Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis. Clin. Drug Investig. 26: 673-676 (2006).

• Ikegawa S, Yamamoto T, Ito H, Ishiwata S, Sakai T, Mitamura K, Maeda M. Identification of lithocholic acid-tagged proteins in the liver of bile duct-ligated rat by means of immunoaffinity capture and MALDI-TOFMS. J. Lipid Res. 49: 2463-2473 (2008). *

• Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, Hayakawa A, Takeshima Y, Sakaeda T, Matsuo M, Okumura K. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J. Hum. Genet. 52: 166-171 (2007). *

• Iser JH, Sali A. Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use. Drugs 21: 90-119 (1981).

• Iverson SL, Uetrecht JP. Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity. Chem. Res. Toxicol. 14: 175-181 (2001). *

• Iwamura K. Clinical studies on cheno- and ursodeoxycholic acid treatment for gallstone dissolution. Hepatogastroenterology 27: 26-34 (1980).

• Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am. J. Cardiol. 97: S44-S51 (2006).

• Jaeschke H. How relevant are neutrophils for acetaminophen hepatotoxicity? Hepatology 43: 1191-1194 (2006). *

• Jaeschke H, Cover C, Bajt ML. Inflammation and drug hepatotoxicity: aggravation of injury or clean-up mission? Hepatology 41: 1176-1178 (2005). *

• Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol. Sci. 65: 166-176 (2002). *

• Jaeschke H, Gujral JS, Bajt ML. Apoptosis and necrosis in liver disease. Liver Int. 24: 85-89 (2004). *

• Jaeschke H, Hasegawa T. Role of neutrophils in acute inflammatory liver injury. Liver Int. 26: 912-919 (2006). *

• James LP, Mayeux PR, Hinson JA. Acetaminophen-induced hepatotoxicity. Drug Metab. Dispos. 31: 1499-1506 (2003). *

• Jaskiewicz K, Voigt H, Blakolmer K. Increased matrix proteins, collagen and transforming growth factor are early markers of hepatotoxicity in patients on long-term methotrexate therapy. J. Toxicol. Clin. Toxicol. 34: 301-305 (1996).

• Jemnitz K, Veres Z, Vereczkey L. Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human. Toxicol. Sci. Feb 10 [Epub ahead of print] (2010). *

• Jeon BR, Lee SM. S-Adenosylmethionine protects post-ischemic mitochondrial injury in rat liver. J. Hepatol. 34: 395-401 (2001).

• Jernigan JD, Harbison RD. Role of biotransformation in the potentiation of halocarbon hepatotoxicity by 2,5-hexanedione. J. Toxicol. Environ. Health 9: 761-781 (1982).

• Jernigan JD, Pounds JG, Harbison RD. Potentiation of chlorinated hydrocarbon toxicity by 2,5-hexanedione in primary cultures of adult rat hepatocytes. Fundam. Appl. Toxicol. 3: 22-26 (1983).

• Ji B, Ito K, Sekine S, Tajima A, Horie T. Ethacrynic-acid-induced glutathione depletion and oxidative stress in normal and Mrp2-deficient rat liver. Free Radic. Biol. Med. 37: 1718-1729 (2004).

• Ji T, Ikehata K, Koen YM, Esch SW, Williams TD, Hanzlik RP. Covalent modification of microsomal lipids by thiobenzamide metabolites in vivo. Chem. Res. Toxicol. 20: 701-708 (2007). *

• Ji Z, Zhang D, Li L, Shen X, Deng X, Dong L, Wu M, Liu Y. The hepatotoxicity of multi-walled carbon nanotubes in mice. Nanotechnology 20: 445101(2009).

• Jia Y, Guo GL, Surapureddi S, Sarkar J, Qi C, Guo D, Xia J, Kashireddi P, Yu S, Cho YW, Rao MS, Kemper B, Ge K, Gonzalez FJ, Reddy JK. Transcription coactivator peroxisome proliferator-activated receptor-binding protein/mediator 1 deficiency abrogates acetaminophen hepatotoxicity. Proc. Natl. Acad. Sci. U.S.A. 102: 12531-12536 (2005). *

• Jorge O, Jorge A. Hepatotoxicity associated with the ingestion of Centella asiatica. Rev. Esp. Enferm. Dig. 97: 115-124 (2005).

• Josephine A, Nithya K, Amudha G, Veena CK, Preetha SP, Varalakshmi P. Role of sulphated polysaccharides from Sargassum wightii in cyclosporine A-induced oxidative liver injury in rats. BMC Pharmacol. 8: 4 (2008). *

• Josse R, Aninat C, Glaise D, Dumont J, Fessard V, Morel F, Poul JM, Guguen-Guillouzo C, Guillouzo A. Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies. Drug Metab. Dispos. 36: 1111-1118 (2008). *

• Jung JW, Park JS, Hwang JW, Kang KS, Lee YS, Song BS, Lee GJ, Yeo CD, Kang JS, Lee WS, Jeon KS, Um CH, Kim YS, Oh MJ, Youn JP, Li P, Park JE, Hwang SY. Gene expression analysis of peroxisome proliferators- and phenytoin-induced hepatotoxicity using cDNA microarray. J. Vet. Med. Sci. 66: 1329-1333 (2004). *

• Kadry AM, Farghali H, Abdel-Rahman MS. Toxicity and metabolism of trichloroethylene in rat hepatocytes. Arch. Environ. Contam. Toxicol. 18: 888-894 (1989).

• Kanada SA, Kolling WM, Hindin BI. Aspirin hepatotoxicity. Am. J. Hosp. Pharm. 35: 330-336 (1978).

• Kandarkar SV, Sawant SS, Ingle AD, Deshpande SS, Maru GB. Subchronic oral hepatotoxicity of turmeric in mice - histopathological and ultrastructural studies. Indian J. Exp. Biol. 36: 675-679 (1998).

• Kang JS, Wanibuchi H, Morimura K, Wongpoomchai R, Chusiri Y, Gonzalez FJ, Fukushima S. Role of CYP2E1 in thioacetamide-induced mouse hepatotoxicity. Toxicol. Appl. Pharmacol. 228: 295-300 (2008). *

• Kannarkat GT, Tuma DJ, Tuma PL. Microtubules are more stable and more highly acetylated in ethanol-treated hepatic cells. J. Hepatol. 44: 963-970 (2006). *

• Kanz MF, Dugas TR, Liu H, Santa Cruz V. Glutathione depletion exacerbates methylenedianiline toxicity to biliary epithelial cells and hepatocytes in rats. Toxicol. Sci. 74: 447-456 (2003). *

• Kao YH, Jawan B, Sun CK, Goto S, Lin YC, Hung CT, Pan MC, Hsu LW, Cheng YF, Lai CY, Wang CS, Tsai CC, Chang HR, Chen CL. High concentration of magnolol induces hepatotoxicity under serum-reduced conditions. Phytomedicine Aug 14 [Epub ahead of print] (2009).

• Kaplan MM, Arora S, Pincus SH. Primary sclerosing cholangitis and low-dose oral pulse methotrexate therapy. Clinical and histologic response. Ann. Intern. Med. 106: 231-235 (1987).

• Kaplowitz N. Statin-induced hepatotoxicity. Gastroenterology 127: 1278 (2004). *

• Kaplowitz N, Aw TY, Simon FR, Stolz A. Drug-induced hepatotoxicity. Ann. Intern. Med. 104: 826-839 (1986).

• Karsenti D, Blanc P, Bacq Y, Metman EH. Hepatotoxicity associated with zolpidem treatment. BMJ 318: 1179 (1999). *

• Kass GE. Mitochondrial involvement in drug-induced hepatic injury. Chem. Biol. Interact. 163: 145-159 (2006). *

• Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J. Am. Acad. Dermatol. 41: S7-S12 (1999).

• Kaufmann P, Torok M, Hanni A, Roberts P, Gasser R, Krahenbuhl S. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 41: 925-935 (2005). *

• Kefalas V, Stacey NH. Potentiating effects of chlorinated hydrocarbons on carbon tetrachloride toxicity in isolated rat hepatocytes and plasma membranes. Toxicol. Appl. Pharmacol. 109: 171-179 (1991).

• Kerr TA, Saeki S, Schneider M, Schaefer K, Berdy S, Redder T, Shan B, Russell DW, Schwarz M. Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. Dev. Cell 2: 713-720 (2002). *

• Kessova IG, Leo MA, Lieber CS. Effect of beta-carotene on hepatic cytochrome P-450 in ethanol-fed rats. Alcohol Clin. Exp. Res. 25: 1368-1372 (2001). *

• Khalili H, Dashti-Khavidaki S, Mohraz M, Etghani A, Almasi F. Antiretroviral induced adverse drug reactions in Iranian human immunodeficiency virus positive patients. Pharmacoepidemiol. Drug Saf. 18: 848-857 (2009).

• Khoo AL, Tham LS, Lee KH, Lim GK. Acute liver failure with concurrent bupropion and carbimazole therapy. Ann. Pharmacother. 37: 220-223 (2003).

• Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int. 26: 943-948 (2006). *

• Kiela PR, Midura AJ, Kuscuoglu N, Jolad SD, Solyom AM, Besselsen DG, Timmermann BN, Ghishan FK. The effects of Boswellia serrata in mouse models of chemically induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G798-G808 (2005). *

• Kim SH, Cheon HJ, Yun N, Oh ST, Shin E, Shim KS, Lee SM. Protective effect of a mixture of Aloe vera and Silybum marianum against carbon tetrachloride-induced acute hepatotoxicity and liver fibrosis. J. Pharmacol. Sci. 109: 119-127 (2009). *

• Kim SK, Kim YC. Attenuation of bacterial lipopolysaccharide-induced hepatotoxicity by betaine or taurine in rats. Food Chem. Toxicol. 40: 545-549 (2002). *

• Kim SK, Kim YC. Effects of betaine supplementation on hepatic metabolism of sulfur-containing amino acids in mice. J. Hepatol. 42: 907-913 (2005). *

• Kim SK, Seo JM, Chae YR, Jung YS, Park JH, Kim YC. Alleviation of dimethylnitrosamine-induced liver injury and fibrosis by betaine supplementation in rats. Chem. Biol. Interact. 177: 204-211 (2009). *

• Kim YC, Jung YS, Kim SK. Effect of betaine supplementation on changes in hepatic metabolism of sulfur-containing amino acids and experimental cholestasis induced by alpha-naphthylisothiocyanate. Food Chem. Toxicol. 43: 663-670 (2005). *

• Kim YH, Shin MJ. Effects of high taurocholate load on activities of hepatic alcohol metabolizing enzymes. Exp. Mol. Med. 34: 123-130 (2002). *

• Kim YJ, Bae SC, Sung YK, Kim TH, Jun JB, Yoo DH, Kim TY, Sohn JH, Lee HS. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J. Rheumatol. Dec 15 [Epub ahead of print] (2009).

• Klein D, Arora U, Lichtmannegger J, Finckh M, Heinzmann U, Summer KH. Tetrathiomolybdate in the treatment of acute hepatitis in an animal model for Wilson disease. J. Hepatol. 40: 409-416 (2004). *

• Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin. Pharmacokinet. 46: 645-660 (2007).

• Knight C, Murray KF. Hepatobiliary associations with inflammatory bowel disease. Expert Rev. Gastroenterol. Hepatol. 3: 681-691 (2009).

• Ko K, Yang H, Noureddin M, Iglesia-Ara A, Xia M, Wagner C, Luka Z, Mato JM, Lu SC. Changes in S-adenosylmethionine and GSH homeostasis during endotoxemia in mice. Lab. Invest. 88: 1121-1129 (2008). *

• Kobayashi E, Kobayashi M, Tsuneyama K, Fukami T, Nakajima M, Yokoi T. Halothane-induced liver injury is mediated by interleukin-17 in mice. Toxicol. Sci. 111: 302-310 (2009). *

• Kobayashi K, Ito K, Takada T, Sugiyama Y, Suzuki H. Functional analysis of nonsynonymous single nucleotide polymorphism type ATP-binding cassette transmembrane transporter subfamily C member 3. Pharmacogenet. Genomics 18: 823-833 (2008).

• Kodali P, Wu P, Lahiji PA, Brown EJ, Maher JJ. ANIT toxicity toward mouse hepatocytes in vivo is mediated primarily by neutrophils via CD18. Am. J. Physiol. Gastrointest. Liver Physiol. 291: G355-G363 (2006). *

• Koller T, Banarova A, Ondrias F, Kollerova J, Payer J. Acute cholestasis following treatment with nimesulide and oral contraception: case report and review. Vnitr. Lek. 54: 665-669 (2008).

• Koo J, Khera P. Update on the mechanisms and efficacy of biological therapies for psoriasis. J. Dermatol. Sci. 38: 75-87 (2005).

• Kooy A, de Heide LJ, Engelkens HJ, Mulder AH, van Hagen M, Schalm SW. Hepatitis in a patient with SLE: is it autoimmune hepatitis? Neth. J. Med. 48: 128-132 (1996).

• Kostrubsky SE, Strom SC, Kalgutkar AS, Kulkarni S, Atherton J, Mireles R, Kubik R, Hanson J, Urda E, Mutlib AE. Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci. 90: 451-459 (2006). *

• Kouklakis G, Mpoumponaris A, Zezos P, Moschos J, Koulaouzidis A, Nakos A, Pehlivanidis A, Iosiphidis M, Molyvas E, Nikolaidis N. Cholestatic hepatitis with severe systemic reactions induced by trimethoprim-sulfamethoxazole. Ann. Hepatol. 6: 63-65 (2007). *

• Koulaouzidis A, Bhat S, Moschos J, Tan C, De Ramon A. Nitrofurantoin-induced lung- and hepatotoxicity. Ann. Hepatol. 6: 119-121 (2007). *

• Kramer JA, Blomme EA, Bunch RT, Davila JC, Jackson CJ, Jones PF, Kolaja KL, Curtiss SW. Transcription profiling distinguishes dose-dependent effects in the livers of rats treated with clofibrate. Toxicol. Pathol. 31: 417-431 (2003). *

• Kretschmer NW, Boor PJ, el Azhary RA, Ahmed AE, Reynolds ES. Studies on the mechanism of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU)-induced hepatotoxicity. III. Ultrastructural characterization of bile duct injury. Cancer Chemother. Pharmacol. 19: 109-117 (1987).

• Krishnan PV, Feng ZZ, Gordon SC. Prolonged intrahepatic cholestasis and renal failure secondary to anabolic androgenic steroid-enriched dietary supplements. J. Clin. Gastroenterol. 43: 672-675 (2009).

• Kroger H, Klewer M, Gratz R, Dietrich A, Ockenfels H, Miesel R. Exacerbation of acetaminophen hepatotoxicity by thalidomide and protection by nicotinic acid amide. Gen. Pharmacol. 26: 1243-1247 (1995). *

• Kroll DJ, Shaw HS, Oberlies NH. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr. Cancer Ther. 6: 110-119 (2007).

• Ku NO, Wright TL, Terrault NA, Gish R, Omary MB. Mutation of human keratin 18 in association with cryptogenic cirrhosis. J. Clin. Invest. 99: 19-23 (1997). *

• Kullak-Ublick GA, Stieger B, Hagenbuch B, Meier PJ. Hepatic transport of bile salts. Semin. Liver Dis. 20: 273-292 (2000). *

• Kumar NB, Allen K, Bell H. Perioperative herbal supplement use in cancer patients: potential implications and recommendations for presurgical screening. Cancer Control 12: 149-157 (2005). *

• Kumar P, Prasad AK, Maji BK, Mani U, Dutta KK. Hepatoxic alterations induced by inhalation of trichlorethylene (TCE) in rats. Biomed. Environ. Sci. 14: 325-332 (2001).

• Kumar S, Qiu H, Oezguen N, Herlyn H, Halpert JR, Wojnowski L. Ligand diversity of human and chimpanzee CYP3A4: activation of human CYP3A4 by lithocholic acid results from positive selection. Drug Metab. Dispos. 37: 1328-1333 (2009). *

• Kumpf VJ. Parenteral nutrition-associated liver disease in adult and pediatric patients. Nutr. Clin. Pract. 21: 279-290 (2006). *

• Kuo FY, Swanson PE, Yeh MM. Pancreatic acinar tissue in liver explants: a morphologic and immunohistochemical study. Am. J. Surg. Pathol. 33: 66-71 (2009).

• Kvasnicka F, Biba B, Sevcik R, Voldrich M, Kratka J. Analysis of the active components of silymarin. J. Chromatogr. A. 990: 239-245 (2003).

• Labib R, Turkall R, Abdel-Rahman MS. Endotoxin potentiates the hepatotoxicity of cocaine in male mice. J. Toxicol. Environ. Health A. 65: 977-993 (2002).

• Lacour S, Gautier JC, Pallardy M, Roberts R. Cytokines as potential biomarkers of liver toxicity. Cancer Biomark. 1: 29-39 (2005).

• Laine L, Goldkind L, Curtis SP, Connors LG, Yanqiong Z, Cannon CP. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am. J. Gastroenterol. 104: 356-362 (2009).

• Laleman W, Van Landeghem L, Van der Elst I, Zeegers M, Fevery J, Nevens F. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology 132: 709-719 (2007). *

• Laliberte L, Villeneuve JP. Hepatitis after the use of germander, a herbal remedy. CMAJ 154: 1689-1692 (1996). *

• Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 51: 615-620 (2010).

• Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 47: 2003-2009 (2008). *

• Lammert F, Marschall HU, Matern S. Intrahepatic cholestasis of pregnancy. Curr. Treat. Options Gastroenterol. 6: 123-132 (2003).

• Larrey D. Hepatotoxicity of drugs and chemicals. Gastroenterol. Clin. Biol. 33: 1136-1146 (2009).

• Larrey D. Liver involvement in the course of phytotherapy. Presse. Med. 23: 691-693 (1994).

• Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin. Liver Dis. 22: 145-155 (2002).

• Larrey D, Pageaux GP. Drug-induced acute liver failure. Eur. J. Gastroenterol. Hepatol. 17: 141-143 (2005). *

• Larrey D, Vial T, Pauwels A, Castot A, Biour M, David M, Michel H. Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann. Intern. Med. 117: 129-132 (1992).

• Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, Reisch JS, Schiodt FV, Ostapowicz G, Shakil AO, Lee WM. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 42: 1364-1372 (2005). *

• Larson JL, Bull RJ. Effect of ethanol on the metabolism of trichloroethylene. J. Toxicol. Environ. Health 28: 395-406 (1989).

• Lash LH, Xu Y, Elfarra AA, Duescher RJ, Parker JC. Glutathione-dependent metabolism of trichloroethylene in isolated liver and kidney cells of rats and its role in mitochondrial and cellular toxicity. Drug Metab. Dispos. 23: 846-853 (1995).

• Lawrenson RA, Seaman HE, Sundstrom A, Williams TJ, Farmer RD. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf. 23: 333-349 (2000).

• Lazarev AI, Siplivyi GV, Kukureka AV, Siplivaya LE. Effect of UV irradiation and magnetic field on immunometabolic effects of antibiotics immobilized in cell carriers. Bull. Exp. Biol. Med. 145: 717-720 (2008).

• Lazaridis KN, Lindor KD. Primary biliary cirrhosis. Curr. Treat. Options Gastroenterol. 2: 473-480 (1999).

• Lazerow SK, Abdi MS, Lewis JH. Drug-induced liver disease 2004. Curr. Opin. Gastroenterol. 21: 283-292 (2005).

• Leak AM, Rincon-Aznar B. Hepatotoxicity associated with etanercept in psoriatic arthritis. J. Rheumatol. 35: 2286-2287 (2008). *

• Lee GS, Yan JS, Ng RK, Kakar S, Maher JJ. Polyunsaturated fat in the methionine-choline-deficient diet influences hepatic inflammation but not hepatocellular injury. J. Lipid Res. 48: 1885-1896 (2007). *

• Lee JY, Jung da W, Park HA, Kim SJ, Chung JH, Moon CK, Kim YC. Effect of taurine on biliary excretion and metabolism of acetaminophen in male hamsters. Biol. Pharm. Bull. 27: 1792-1796 (2004). *

• Lee S, Dawson PA, Hewavitharana AK, Shaw PN, Markovich D. Disruption of NaS1 sulfate transport function in mice leads to enhanced acetaminophen-induced hepatotoxicity. Hepatology 43: 1241-1247 (2006). *

• Lee S, Kim S, Le HD, Meisel J, Strijbosch RA, Nose V, Puder M. Reduction of hepatocellular injury after common bile duct ligation using omega-3 fatty acids. J. Pediatr. Surg. 43: 2010-2015 (2008).

• Lee WM. Acute liver failure in the United States. Semin. Liver Dis. 23: 217-226 (2003).

• Lee WM. Drug-induced hepatotoxicity. N. Engl. J. Med. 349: 474-485 (2003). *

• Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol. Pathol. 33: 155-164 (2005). *

• Lee YM, Teo EK, Ng TM, Khor C, Fock KM. Autoimmune hepatitis in Singapore: a rare syndrome affecting middle-aged women. J. Gastroenterol. Hepatol. 16: 1384-1389 (2001). *

• Lees CW, Mann A, Hansoni B, Arnott SJ. Tolerability and safety of mercaptopurine in azathioprine intolerant patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 27: 220-227 (2008). *

• Leeuwenburgh I, Lugtenburg EP, van Buuren HR, Zondervan PE, de Man RA. Severe jaundice, due to vanishing bile duct syndrome, as presenting symptom of Hodgkin's lymphoma, fully reversible after chemotherapy. Eur. J. Gastroenterol. Hepatol. 20: 145-147 (2008).

• Lefkowitch JH. Pathology of AIDS-related liver disease. Dig. Dis. 12: 321-330 (1994).

• Lefkowitch JH. Liver histopathology. Clin. Liver Dis. 6: xv-xix (2002). *

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 23: 221-231 (2007).

• Leiro V, Fernandez-Villar A, Valverde D, Constenla L, Vazquez R, Pineiro L, Gonzalez-Quintela A. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int. 28: 835-839 (2008).

• Leithead JA, Simpson KJ, Macgilchrist AJ. Fulminant hepatic failure following overdose of the vitamin A metabolite acitretin. Eur. J. Gastroenterol. Hepatol. 21: 230-232 (2009).

• Leo MA, Aleynik SI, Aleynik MK, Lieber CS. beta-Carotene beadlets potentiate hepatotoxicity of alcohol. Am. J. Clin. Nutr. 66: 1461-1469 (1997). *

• Leo MA, Kim C, Lowe N, Lieber CS. Interaction of ethanol with beta-carotene: delayed blood clearance and enhanced hepatotoxicity. Hepatology 15: 883-891 (1992).

• Leo MA, Lieber CS. Alcohol, vitamin A, and beta-carotene: adverse interactions, including hepatotoxicity and carcinogenicity. Am. J. Clin. Nutr. 69: 1071-1085 (1999). *

• Leong RW, Gearry RB, Sparrow MP. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol. Expert Opin. Drug Saf. 7: 607-616 (2008).

• Leslie EM, Watkins PB, Kim RB, Brouwer KL. Differential inhibition of rat and human Na+-dependent taurocholate co-transporting polypeptide (NTCP/SLC10A1) by bosentan: a mechanism for species differences in hepatotoxicity. J. Pharmacol. Exp. Ther. 321: 1170-1178 (2007). *

• Levinson JR, Gordon SC. Liver diseases in the elderly. Clin. Geriatr. Med. 7: 371-385 (1991).

• Levy C, Lindor KD. Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis. Curr. Treat. Options Gastroenterol. 6: 93-103 (2003).

• Levy C, Lindor KD. Management of primary biliary cirrhosis. Curr. Treat. Options Gastroenterol. 6: 493-498 (2003).

• Lewis JH. Drug-induced liver disease. Curr. Opin. Gastroenterol. 18: 307-313 (2002).

• Lewis JH, Ahmed M, Shobassy A, Palese C. Drug-induced liver disease. Curr. Opin. Gastroenterol. 22: 223-233 (2006).

• Li Z, Diehl AM. Innate immunity in the liver. Curr. Opin. Gastroenterol. 19: 565-571 (2003).

• Li Z, Oben JA, Yang S, Lin H, Stafford EA, Soloski MJ, Thomas SA, Diehl AM. Norepinephrine regulates hepatic innate immune system in leptin-deficient mice with nonalcoholic steatohepatitis. Hepatology 40: 434-441 (2004). *

• Liangpunsakul S, Chalasani N. Treatment of nonalcoholic fatty liver disease. Curr. Treat. Options Gastroenterol. 6: 455-463 (2003).

• Lieber CS. Mechanisms of ethanol-drug-nutrition interactions. J. Toxicol. Clin. Toxicol. 32: 631-681 (1994).

• Lieber CS. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol 34: 9-19 (2004). *

• Lieber CS. Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998) - a review. Alcohol Clin. Exp. Res. 23: 991-1007 (1999). *

• Lieber CS. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab. Rev. 36: 511-529 (2004). *

• Lieber CS. Hepatic and metabolic effects of ethanol: pathogenesis and prevention. Ann. Med. 26: 325-330 (1994).

• Lieber CS. Hepatic, metabolic and toxic effects of ethanol: 1991 update. Alcohol Clin. Exp. Res. 15: 573-592 (1991). *

• Lieber CS. Biochemical factors in alcoholic liver disease. Semin. Liver Dis. 13: 136-153 (1993).

• Lieber CS. Alcohol, liver, and nutrition. J. Am. Coll. Nutr. 10: 602-632 (1991).

• Lieber CS. Interaction of alcohol with other drugs and nutrients. Implication for the therapy of alcoholic liver disease. Drugs 40 Suppl. 3: 23-44 (1990).

• Lieber CS, Decarli LM, Leo MA, Mak KM, Ponomarenko A, Ren C, Wang X. Beneficial effects versus toxicity of medium-chain triacylglycerols in rats with NASH. J. Hepatol. 48: 318-326 (2008). *

• Lieu HT, Simon MT, Nguyen-Khoa T, Kebede M, Cortes A, Tebar L, Smith AJ, Bayne R, Hunt SP, Brechot C, Christa L. Reg2 inactivation increases sensitivity to Fas hepatotoxicity and delays liver regeneration post-hepatectomy in mice. Hepatology 44: 1452-1464 (2006). *

• Liguori MJ, Anderson MG, Bukofzer S, McKim J, Pregenzer JF, Retief J, Spear BB, Waring JF. Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology 41: 177-186 (2005). *

• Lim JR, Faught PR, Chalasani NP, Molleston JP. Severe liver injury after initiating therapy with atomoxetine in two children. J. Pediatr. 148: 831-834 (2006). *

• Limaye PB, Bhave VS, Palkar PS, Apte UM, Sawant SP, Yu S, Latendresse JR, Reddy JK, Mehendale HM. Upregulation of calpastatin in regenerating and developing rat liver: role in resistance against hepatotoxicity. Hepatology 44: 379-388 (2006). *

• Lin CC, Yin MC, Liu WH. Alleviative effects of S-allyl cysteine and S-ethyl cysteine on MCD diet-induced hepatotoxicity in mice. Food Chem. Toxicol. 46: 3401-3406 (2008). *

• Lin Y, Si D, Zhang Z, Liu C. An integrated metabonomic method for profiling of metabolic changes in carbon tetrachloride induced rat urine. Toxicology 256: 191-200 (2009). *

• Linares V, Alonso V, Albina ML, Belles M, Sirvent JJ, Domingo JL, Sanchez DJ. Lipid peroxidation and antioxidant status in kidney and liver of rats treated with sulfasalazine. Toxicology 256: 152-156 (2009). *

• Link KH, Sunelaitis E, Kornmann M, Schatz M, Gansauge F, Leder G, Formentini A, Staib L, Pillasch J, Beger HG. Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival. Cancer 92: 2746-2753 (2001). *

• Lipscomb JC, Teuschler LK, Swartout J, Popken D, Cox T, Kedderis GL. The impact of cytochrome P450 2E1-dependent metabolic variance on a risk-relevant pharmacokinetic outcome in humans. Risk Anal. 23: 1221-1238 (2003).

• Lirussi F, Okolicsanyi L. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease. Ital. J. Gastroenterol. 24: 31-35 (1992).

• Liu J, He YY, Chignell CF, Clark J, Myers P, Saavedra JE, Waalkes MP. Limited protective role of V-PYRRO/NO against cholestasis produced by alpha-naphthylisothiocyanate in mice. Biochem. Pharmacol. 70: 144-151 (2005). *

• Liu J, Zhou ZX, Zhang W, Bell MW, Waalkes MP. Changes in hepatic gene expression in response to hepatoprotective levels of zinc. Liver Int. 29: 1222-1229 (2009). *

• Liu LL, Feng ML, Wang LN, Li XL, Yao L. A case report of successful treatment with plasma exchange for adult-onset Still's disease with autoimmune hepatitis. J. Clin. Apher. Jan 25 [Epub ahead of print] (2010).

• Liu ZX, Govindarajan S, Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 127: 1760-1774 (2004). *

• Liu ZX, Han D, Gunawan B, Kaplowitz N. Neutrophil depletion protects against murine acetaminophen hepatotoxicity. Hepatology 43: 1220-1230 (2006). *

• Liu ZX, Kaplowitz N. Chapter 28. Immune mechanisms in drug-induced hepatotoxicity: therapeutic implications. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 363-374 (2007). *

• Lopez-Torres E, Lucena MI, Seoane J, Verge C, Andrade RJ. Hepatotoxicity related to citalopram. Am. J. Psychiatry 161: 923-924 (2004). *

• Low TY, Leow CK, Salto-Tellez M, Chung MC. A proteomic analysis of thioacetamide-induced hepatotoxicity and cirrhosis in rat livers. Proteomics 4: 3960-3974 (2004). *

• Lowenthal KE, Horn PJ, Kalb RE. Concurrent use of methotrexate and acitretin revisited. J. Dermatolog. Treat. 19: 22-26 (2008).

• Lu H, Choudhuri S, Ogura K, Csanaky IL, Lei X, Cheng X, Song PZ, Klaassen CD. Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and microcystin-LR. Toxicol. Sci. 103: 35-45 (2008). *

• Lu Y, Cederbaum AI. CYP2E1 potentiation of LPS and TNFalpha-induced hepatotoxicity by mechanisms involving enhanced oxidative and nitrosative stress, activation of MAP kinases, and mitochondrial dysfunction. Genes Nutr. Oct 2 [Epub ahead of print] (2009). *

• Luca G, Orietta S, Caterina P, Giovambattista DS, Maria F. Hepatotoxicity induced by methimazole in a previously healthy patient. Curr. Drug Saf. 4: 204-206 (2009).

• Lucena MI, Andrade RJ, Fernandez MC, Pachkoria K, Pelaez G, Duran JA, Villar M, Rodrigo L, Romero-Gomez M, Planas R, Barriocanal A, Costa J, Guarner C, Blanco S, Navarro JM, Pons F, Castiella A, Avila S. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 44: 850-856 (2006). *

• Lucena MI, Andrade RJ, Kaplowitz N, García-Cortes M, Fernandez MC, Romero-Gomez M, Bruguera M, Hallal H, Robles-Diaz M, Rodriguez-Gonzalez JF, Navarro JM, Salmeron J, Martinez-Odriozola P, Perez-Alvarez R, Borraz Y, Hidalgo R. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 49: 2001-2009 (2009).

• Lucena MI, Andrade RJ, Martinez C, Ulzurrun E, Garcia-Martin E, Borraz Y, Fernandez MC, Romero-Gomez M, Castiella A, Planas R, Costa J, Anzola S, Agundez JA; Spanish Group for the Study of Drug-Induced Liver Disease. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 48: 588-596 (2008). *

• Lucena MI, Andrade RJ, Vicioso L, Gonzalez FJ, Pachkoria K, Garcia-Munoz B. Prolonged cholestasis after raloxifene and fenofibrate interaction: a case report. World J. Gastroenterol. 12: 5244-5246 (2006). *

• Lundberg I, Ekdahl M, Kronevi T, Lidums V, Lundberg S. Relative hepatotoxicity of some industrial solvents after intraperitoneal injection or inhalation exposure in rats. Environ. Res. 40: 411-420 (1986).

• Luster MI, Simeonova PP, Gallucci RM, Matheson JM, Yucesoy B. Immunotoxicology: role of inflammation in chemical-induced hepatotoxicity. Int. J. Immunopharmacol. 22: 1143-1147 (2000).

• Luyendyk JP, Cantor GH, Kirchhofer D, Mackman N, Copple BL, Wang R. Tissue factor-dependent coagulation contributes to alpha-naphthylisothiocyanate-induced cholestatic liver injury in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G840-G849 (2009). *

• Luyendyk JP, Maddox JF, Green CD, Ganey PE, Roth RA. Role of hepatic fibrin in idiosyncrasy-like liver injury from lipopolysaccharide-ranitidine coexposure in rats. Hepatology 40: 1342-1351 (2004). *

• Luyendyk JP, Shores KC, Ganey PE, Roth RA. Bacterial lipopolysaccharide exposure alters aflatoxin B(1) hepatotoxicity: benchmark dose analysis for markers of liver injury. Toxicol. Sci. 68: 220-225 (2002). *

• Lynch M, Kirby B. Comment on: hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate. Rheumatology (Oxford) 49: 196-197 (2010).

• MacDonald JR, Gandolfi AJ, Sipes IG. Acetone potentiation of 1,1,2-trichloroethane hepatotoxicity. Toxicol. Lett. 13: 57-69 (1982).

• MacDonald JR, Gandolfi AJ, Sipes IG. Covalent binding of 14C-1,1,2-trichloroethane to hepatic proteins following acetone pretreatment. Drug Chem. Toxicol. 5: 233-247 (1982).

• Maddox JF, Amuzie CJ, Li M, Newport SW, Sparkenbaugh E, Cuff CF, Pestka JJ, Cantor GH, Roth RA, Ganey PE. Bacterial- and viral-induced inflammation increases sensitivity to acetaminophen hepatotoxicity. J. Toxicol. Environ. Health A. 73: 58-73 (2010).

• Maddrey WC. Drug-induced hepatotoxicity: 2005. J. Clin. Gastroenterol. 39: S83-S89 (2005).

• Mahadevan U, Sandborn WJ. Evolving medical therapies for Crohn's disease. Curr. Gastroenterol. Rep. 3: 471-476 (2001).

• Mahadevan U, Tremaine WJ, Johnson T, Pike MG, Mays DC, Lipsky JJ, Sandborn WJ. Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am. J. Gastroenterol. 95: 3463-3468 (2000). *

• Majewska M, Zajac K, Kubera M, Bryniarski K, Ptak M, Basta-Kaim A, Ksiazek L, Ptak W, Lason W, Szczepanik M. Effect of ovoalbumin on the survival of an H-Y incompatible skin graft in C57BL/6 mice. Pharmacol. Rep. 58: 439-442 (2006). *

• Makarova SI. Human N-acetyltransferases and drug-induced hepatotoxicity. Curr. Drug Metab. 9: 538-545 (2008).

• Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR,Mangelsdorf DJ. Vitamin D receptor as an intestinal bile acid sensor. Science 296: 1313-1316 (2002). *

• Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology 43: S31-S44 (2006). *

• Mambelli E, Mancini E, Casanova S, Di Felice A, Santoro A. Severe ticlopidine-induced cholestatic syndrome. Blood Purif. 25: 441-445 (2007). *

• Manautou JE, de Waart DR, Kunne C, Zelcer N, Goedken M, Borst P, Oude Elferink RP. Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. Hepatology 42: 1091-1098 (2005). *

• Mancini S, Amorotti E, Vecchio S, Ponz de Leon M, Roncucci L. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern. Emerg. Med. Jan 27 [Epub ahead of print] (2010).

• Marcy TR, Britton ML, Blevins SM. Second-generation thiazolidinediones and hepatotoxicity. Ann. Pharmacother. 38: 1419-1423 (2004).

• Marek CJ, Tucker SJ, Konstantinou DK, Elrick LJ, Haefner D, Sigalas C, Murray GI, Goodwin B, Wright MC. Pregnenolone 16alpha carbonitrile inhibits rodent liver fibrogenesis via PXR (pregnane X receptor)-dependent and PXR-independent mechanisms. Biochem. J. 387: 601-708 (2005). *

• Marion TL, Leslie EM, Brouwer KL. Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity. Mol. Pharm. 4: 911-918 (2007). *

• Marschall HU, Wagner M, Zollner G, Trauner M. Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors. Mol. Pharm. 4: 895-910 (2007). *

• Martin P. Key consultations in hepatology. Preface. Clin. Liver Dis. 13: xi-xii (2009). *

• Martinez-Chantar ML, Corrales FJ, Martinez-Cruz LA, Garcia-Trevijano ER, Huang ZZ, Chen L, Kanel G, Avila MA, Mato JM, Lu SC. Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J. 16: 1292-1294 (2002). *

• Marzoa-Rivas R, Crespo-Leiro MG, Paniagua-Marin MJ, Llinares-Garcia D, Muniz-Garcia J, Aldama-Lopez G, Pinon-Esteban P, Campo-Perez R, Castro-Beiras A. Safety of statins when response is carefully monitored: a study of 336 heart recipients. Transplant. Proc. 37: 4071-4073 (2005). *

• Massarotti M, Marasini B. Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity. Int. J. Immunopathol. Pharmacol. 22: 547-549 (2009).

• Masubuchi Y. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab. Pharmacokinet. 21: 347-356 (2006). *

• Masubuchi Y, Suda C, Horie T. Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice. J. Hepatol. 42: 110-116 (2005). *

• Masubuchi Y, Sugiyama S, Horie T. Th1/Th2 cytokine balance as a determinant of acetaminophen-induced liver injury. Chem. Biol. Interact. 179: 273-279 (2009). *

• Matsumoto K, Yu S, Jia Y, Ahmed MR, Viswakarma N, Sarkar J, Kashireddy PV, Rao MS, Karpus W, Gonzalez FJ, Reddy JK. Critical role for transcription coactivator peroxisome proliferator-activated receptor (PPAR)-binding protein/TRAP220 in liver regeneration and PPARalpha ligand-induced liver tumor development. J. Biol. Chem. 282: 17053-17060 (2007). *

• Mauss S, Puoti M. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice - clinical implications for CCR5 inhibition as antiretroviral therapy. Hepatology 43: 879 (2006). *

• Mazzanti G, Menniti-Ippolito F, Moro PA, Cassetti F, Raschetti R, Santuccio C, Mastrangelo S. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur. J. Clin. Pharmacol. 65: 331-341 (2009).

• Mazzella G, Fusaroli P, Pezzoli A, Azzaroli F, Mazzeo C, Zambonin L, Simoni P, Festi D, Roda E. Methylprednisolone administration in primary biliary cirrhosis increases cholic acid turnover, synthesis, and deoxycholate concentration in bile. Dig. Dis. Sci. 44: 2478-2483 (1999). *

• McClain CJ, Barve S, Barve S, Deaciuc I, Hill DB. Tumor necrosis factor and alcoholic liver disease. Alcohol Clin. Exp. Res. 22: 248S-252S (1998).

• McClain CJ, Hill DB, Song Z, Chawla R, Watson WH, Chen T, Barve S. S-Adenosylmethionine, cytokines, and alcoholic liver disease. Alcohol 27: 185-192 (2002). *

• McCormack PL, Keating GM. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 65: 2719-2740 (2005).

• McDonnell ME, Braverman LE. Drug-related hepatotoxicity. N. Engl. J. Med. 354: 2191-2193 (2006). *

• McMillian M, Nie AY, Parker JB, Leone A, Kemmerer M, Bryant S, Herlich J, Yieh L, Bittner A, Liu X, Wan J, Johnson MD. Inverse gene expression patterns for macrophage activating hepatotoxicants and peroxisome proliferators in rat liver. Biochem. Pharmacol. 67: 2141-2165 (2004). *

• McRae M, Rezk NL, Bridges AS, Corbett AH, Tien HC, Brouwer KL, Kashuba AD. Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: possible implications for hepatotoxicity. Pharmacotherapy 30: 17-24 (2010).

• McRae MP, Lowe CM, Tian X, Bourdet DL, Ho RH, Leake BF, Kim RB, Brouwer KL, Kashuba AD. Ritonavir, saquinavir and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J. Pharmacol. Exp. Ther. 318: 1068-1075 (2006). *

• Meissonnier GM, Pinton P, Laffitte J, Cossalter AM, Gong YY, Wild CP, Bertin G, Galtier P, Oswald IP. Immunotoxicity of aflatoxin B1: impairment of the cell-mediated response to vaccine antigen and modulation of cytokine expression. Toxicol. Appl. Pharmacol. 231: 142-149 (2008). *

• Menon KVN, Angulo P, Lindor KD. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. Am. J. Gastroenterol. 96: 1631-1634 (2001). *

• Micu AL, Miksys S, Sellers EM, Koop DR, Tyndale RF. Rat hepatic CYP2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism. J. Pharmacol. Exp. Ther. 306: 941-947 (2003). *

• Miele L, Vallone S, Cefalo C, Torre GL, Stasi CD, Vecchio FM, D'Agostino M, Gabrieli ML, Vero V, Biolato M, Pompili M, Gasbarrini G, Rapaccini G, Amerio P, Simone CD, Grieco A. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J. Hepatol. 51: 778-786 (2009).

• Mieli-Vergani G, Vergani D. Autoimmune liver disease - therapeutic aspects in children. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 89-91 (2004). *

• Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch. Intern. Med. 158: 2200-2211 (1998). *

• Millonig G, Stadlmann S, Vogel W. Herbal hepatotoxicity: acute hepatitis caused by a Noni preparation (Morinda citrifolia). Eur. J. Gastroenterol. Hepatol. 17: 445-447 (2005).

• Mion F, Napoleon B, Berger F, Chevallier M, Bonvoisin S, Descos L. Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis. Gut 32: 715-717 (1991). *

• Mita S, Suzuki H, Akita H, Hayashi H, Onuki R, Hofmann AF, Sugiyama Y. Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab. Dispos. 34: 1575-1581 (2006). *

• Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 48: 1420-1429 (2008). *

• Miyagi T, Takehara T, Tatsumi T, Suzuki T, Jinushi M, Kanazawa Y, Hiramatsu N, Kanto T, Tsuji S, Hori M, Hayashi N. Concanavalin a injection activates intrahepatic innate immune cells to provoke an antitumor effect in murine liver. Hepatology 40: 1190-1196 (2004). *

• Miyai K, Javitt NB, Gochman N, Jones HM, Baker D. Hepatotoxicity of bile acids in rabbits: ursodeoxycholic acid is less toxic than chenodeoxycholic acid. Lab. Invest. 46: 428-437 (1982).

• Miyata M, Watase H, Hori W, Shimada M, Nagata K, Gonzalez FJ, Yamazoe Y. Role for enhanced faecal excretion of bile acid in hydroxysteroid sulfotransferase-mediated protection against lithocholic acid-induced liver toxicity. Xenobiotica 36: 631-644 (2006). *

• Mollinedo F, Gajate C, Morales AI, Del Canto-Janez E, Justies N, Collia F, Rivas JV, Modolell M, Iglesias A. Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitis. J. Pharmacol. Exp. Ther. 329: 439-449 (2009). *

• Monk JP, Todd PA. Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs 33: 539-576 (1987).

• Moore PK, Marshall M. Nitric oxide releasing acetaminophen (nitroacetaminophen). Dig. Liver Dis. 35 Suppl. 2: S49-S60 (2003).

• Mor A, Clifton BO, Kishimoto M, Izmirly PM, Greenberg J, Reddy S, Rosenthal PB. Methotrexate combined with isoniazid therapy for latent tuberculosis is well tolerated in rheumatoid arthritis patients: experience from an urban arthritis clinic. Ann. Rheum. Dis. 67: 462-465 (2008).

• Moreno C, Deviere J, Louis H. Reply to "CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice - clinical implications for CCR5 inhibition as antiretroviral therapy". Hepatology 43: 879-880 (2006).

• Mortishire-Smith RJ, Skiles GL, Lawrence JW, Spence S, Nicholls AW, Johnson BA, Nicholson JK. Use of metabonomics to identify impaired fatty acid metabolism as the mechanism of a drug-induced toxicity. Chem. Res. Toxicol. 17: 165-173 (2004). *

• Mottino AD, Catania VA. Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents. World J. Gastroenterol. 14: 7068-7074 (2008). *

• Mugica F, Castiella A, Otazua P, Munagorri A, Recasens M, Barrio J, Elosegui E. Prevalence of coeliac disease in unexplained chronic hypertransaminasemia. Rev. Esp. Enferm. Dig. 93: 707-714 (2001).

• Murray KF, Hadzic N, Wirth S, Bassett M, Kelly D. Drug-related hepatotoxicity and acute liver failure. J. Pediatr. Gastroenterol. Nutr. 47: 395-405 (2008). *

• Nakagawa S, Makino I, Ishizaki T, Dohi I. Dissolution of cholesterol gallstones by ursodeoxycholic acid. Lancet 2: 367-369 (1977).

• Nakajima T, Okino T, Okuyama S, Kaneko T, Yonekura I, Sato A. Ethanol-induced enhancement of trichloroethylene metabolism and hepatotoxicity: difference from the effect of phenobarbital. Toxicol. Appl. Pharmacol. 94: 227-237 (1988).

• Nakashima H, Inui T, Habu Y, Kinoshita M, Nagao S, Kawaguchi A, Miura S, Shinomiya N, Yagita H, Seki S. Activation of mouse natural killer T cells accelerates liver regeneration after partial hepatectomy. Gastroenterology 131: 1573-1583 (2006). *

• Namazi MR. Nicotinamide: a potential addition to the anti-psoriatic weaponry. FASEB J. 17: 1377-1379 (2003). *

• Napirei M, Basnakian AG, Apostolov EO, Mannherz HG. Deoxyribonuclease 1 aggravates acetaminophen-induced liver necrosis in male CD-1 mice. Hepatology 43: 297-305 (2006). *

• Navarro VJ, Senior JR. Drug-related hepatotoxicity. N. Engl. J. Med. 354: 731-739 (2006). *

• Neff GW, Rajender Reddy K, Durazo FA, Meyer D, Marrero R, Kaplowitz N. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. J. Hepatol. 41: 1062-1064 (2004). *

• Neff GW, Ruiz P, Madariaga JR, Nishida S, Montalbano M, Meyer D, Levi DM, Tzakis AG, O'Brien CB. Sirolimus-associated hepatotoxicity in liver transplantation. Ann. Pharmacother. 38: 1593-1596 (2004).

• Neuberger J. Liver transplantation for cholestatic liver disease. Curr. Treat. Options Gastroenterol. 6: 113-121 (2003).

• Neumeier M, Weigert J, Schaffler A, Weiss T, Kirchner S, Laberer S, Scholmerich J, Buechler C. Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors. Biochem. Biophys. Res. Commun. 334: 924-929 (2005). *

• Neyrinck AM, Mouson A, Delzenne NM. Dietary supplementation with laminarin, a fermentable marine beta (1-3) glucan, protects against hepatotoxicity induced by LPS in rat by modulating immune response in the hepatic tissue. Int. Immunopharmacol. 7: 1497-1506 (2007).

• Nguyen KA, Carbone JM, Silva VM, Chen C, Hennig GE, Whiteley HE, Manautou JE. The PPAR activator docosahexaenoic acid prevents acetaminophen hepatotoxicity in male CD-1 mice. J. Toxicol. Environ. Health A. 58: 171-186 (1999).

• Nishiya T, Kato M, Suzuki T, Maru C, Kataoka H, Hattori C, Mori K, Jindo T, Tanaka Y, Manabe S. Involvement of cytochrome P450-mediated metabolism in tienilic acid hepatotoxicity in rats. Toxicol. Lett. 183: 81-89 (2008).

• Nomoto M, Miyata M, Shimada M, Yoshinari K, Gonzalez FJ, Shibasaki S, Kurosawa T, Shindo Y, Yamazoe Y. ME3738 protects against lithocholic acid-induced hepatotoxicity, which is associated with enhancement of biliary bile acid and cholesterol output. Eur. J. Pharmacol. 574: 192-200 (2007). *

• Nozawa T, Sugiura S, Nakajima M, Goto A, Yokoi T, Nezu J, Tsuji A, Tamai I. Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab. Dispos. 32: 291-294 (2004). *

• Nukaya M, Moran S, Bradfield CA. The role of the dioxin-responsive element cluster between the Cyp1a1 and Cyp1a2 loci in aryl hydrocarbon receptor biology. Proc. Natl. Acad. Sci. U.S.A. 106: 4923-4928 (2009). *

• Numata K, Kubo M, Watanabe H, Takagi K, Mizuta H, Okada S, Kunkel SL, Ito T, Matsukawa A. Overexpression of suppressor of cytokine signaling-3 in T cells exacerbates acetaminophen-induced hepatotoxicity. J. Immunol. 178: 3777-3785 (2007). *

• Nunes de Paiva MJ, Pereira Bastos de Siqueira ME. Increased serum bile acids as a possible biomarker of hepatotoxicity in Brazilian workers exposed to solvents in car repainting shops. Biomarkers 10: 456-463 (2005).

• O'Brien SM, Campbell GR, Burke AF, Maguire OC, Rowlands BJ, FitzGerald MX, Hegarty JE. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease. Eur. J. Gastroenterol. Hepatol. 8: 477-483 (1996).

• O'Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RN, Mills PR. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 47: 717-720 (2000). *

• O'Grady JG. Broadening the view of acetaminophen hepatotoxicity. Hepatology 42: 1252-1254 (2005). *

• Ohta Y, Kongo-Nishimura M, Imai Y, Matsura T, Kitagawa A, Yamada K. alpha-Tocopherol protects against alpha-naphthylisothiocyanate-induced hepatotoxicity in rats less effectively than melatonin. Chem. Biol. Interact. 161: 115-124 (2006). *

• Okino T, Nakajima T, Nakano M. Morphological and biochemical analyses of trichloroethylene hepatotoxicity: differences in ethanol- and phenobarbital-pretreated rats. Toxicol. Appl. Pharmacol. 108: 379-389 (1991).

• Olomu AB, Vickers CR, Waring RH, Clements D, Babbs C, Warnes TW, Elias E. High incidence of poor sulfoxidation in patients with primary biliary cirrhosis. N. Engl. J. Med. 318: 1089-1092 (1988).

• Onder C, Bengur T, Kirci A, Mine T, Zafer B, Belkis U, Kadir A, Gazi Y. Etiological role of brucellosis in autoimmune hepatitis. World J. Gastroenterol. 11: 2200-2202 (2005). *

• Ooi CY, Bohane TD, Lee D, Naidoo D, Day AS. Thiopurine metabolite monitoring in paediatric inflammatory bowel disease. Aliment. Pharmacol. Ther. 25: 941-947 (2007). *

• Osman E, Owen JS, Burroughs AK. Review article: S-adenosyl-L-methionine - a new therapeutic agent in liver disease? Aliment. Pharmacol. Ther. 7: 21-28 (1993).

• Owen BM, Milona A, van Mil S, Clements P, Holder J, Boudjelal M, Cairns W, Parker M, White R, Williamson C. Intestinal detoxification limits the activation of hepatic pregnane X receptor by lithocholic acid. Drug Metab. Dispos. 38: 143-149 (2010). *

• Oz HS, Chen TS. Green-tea polyphenols downregulate cyclooxygenase and Bcl-2 activity in acetaminophen-induced hepatotoxicity. Dig. Dis. Sci. 53: 2980-2988 (2008). *

• Oz HS, McClain CJ, Nagasawa HT, Ray MB, de Villiers WJ, Chen TS. Diverse antioxidants protect against acetaminophen hepatotoxicity. J. Biochem. Mol. Toxicol. 18: 361-368 (2005). *

• Pachkoria K, Lucena MI, Molokhia M, Cueto R, Carballo AS, Carvajal A, Andrade RJ. Genetic and molecular factors in drug-induced liver injury: a review. Curr. Drug Saf. 2: 97-112 (2007). *

• Palomero J, Galan AI, Munoz ME, Tunon MJ, Gonzalez-Gallego J, Jimenez R. Effects of aging on the susceptibility to the toxic effects of cyclosporin A in rats. Changes in liver glutathione and antioxidant enzymes. Free Radic. Biol. Med. 30: 836-845 (2001).

• Papa S, Bubici C, Zazzeroni F, Franzoso G. Mechanisms of liver disease: the crosstalk between the NF-kappaB and JNK pathways. Biol. Chem. 390: 965-976 (2009).

• Papa S, Zazzeroni F, Fu YX, Bubici C, Alvarez K, Dean K, Christiansen PA, Anders RA, Franzoso G. Gadd45beta promotes hepatocyte survival during liver regeneration in mice by modulating JNK signaling. J. Clin. Invest. 118: 1911-1923 (2008). *

• Pari L, Sivasankari R. Effect of ellagic acid on cyclosporine A-induced oxidative damage in the liver of rats. Fundam. Clin. Pharmacol. 22: 395-401 (2008).

• Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP. The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol. 45: 177-202 (2005). *

• Pastor A, Collado PS, Almar M, Gonzalez-Gallego J. Microsomal function in biliary obstructed rats: effects of S-adenosylmethionine. J. Hepatol. 24: 353-359 (1996). *

• Pattinson NR, Chapman BA. Lithocholate detoxification and biliary secretion in the rat. Biochem. Int. 9: 137-142 (1984).

• Pazzi P, Puviani AC, Dalla Libera M, Guerra G, Ricci D, Gullini S, Ottolenghi C. Bile salt-induced cytotoxicity and ursodeoxycholate cytoprotection: in-vitro study in perifused rat hepatocytes. Eur. J. Gastroenterol. Hepatol. 9: 703-709 (1997).

• Petit E, Langouet S, Akhdar H, Nicolas-Nicolaz C, Guillouzo A, Morel F. Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. Toxicol. In Vitro 22: 632-642 (2008).

• Pettersson J, Hindorf U, Persson P, Bengtsson T, Malmqvist U, Werkstrom V, Ekelund M. Muscular exercise can cause highly pathological liver function tests in healthy men. Br. J. Clin. Pharmacol. 65: 253-359 (2008). *

• Piazza F, Montagnani M, Russo C, Azzaroli F, Aldini R, Roda E, Roda A. Competition in liver transport between chenodeoxycholic acid and ursodeoxycholic acid as a mechanism for ursodeoxycholic acid and its amidates' protection of liver damage induced by chenodeoxycholic acid. Dig. Liver Dis. 32: 318-328 (2000).

• Pien EH, Zeman RK, Benjamin SB, Barth KH, Jaffe MH, Choyke PL, Clark LR, Paushter DM. Iatrogenic sclerosing cholangitis following hepatic arterial chemotherapy infusion. Radiology 156: 329-330 (1985). *

• Pishvaian AC, Trope BW, Lewis JH. Drug-induced liver disease in 2003. Curr. Opin. Gastroenterol. 20: 208-219 (2004).

• Pittler MH, Ernst E. Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment. Pharmacol. Ther. 18: 451-471 (2003). *

• Podda M, Ghezzi C, Battezzati PM, Bertolini E, Crosignani A, Petroni ML, Zuin M. Ursodeoxycholic acid for chronic liver diseases. J. Clin. Gastroenterol. 10 Suppl. 2: S25-S31 (1988).

• Poniachik J, Guerrero J, Calderon P, Smok G, Morales A, Munoz G, Venegas M. Cholestatic hepatitis associated with piroxicam use. Case report. Rev. Med. Chil. 126: 548-552 (1998).

• Potthoff A, Deterding K, Trautwein C, Flemming P, Strassburg CP, Manns MP, Wedemeyer H, Bahr MJ. Steroid treatment for severe acute cryptogenic hepatitis. Z. Gastroenterol. 45: 15-19 (2007).

• Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N. Engl. J. Med. 324: 1548-1554 (1991).

• Prandota J. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly … Am. J. Ther. 12: 254-261 (2005).

• Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 50: 436-439 (2002). *

• Pugh AJ, Barve AJ, Falkner K, Patel M, McClain CJ. Drug-induced hepatotoxicity or drug-induced liver injury. Clin. Liver Dis. 13: 277-294 (2009).

• Pumford NR, Halmes NC, Hinson JA. Covalent binding of xenobiotics to specific proteins in the liver. Drug Metab. Rev. 29: 39-57 (1997).

• Qasim A, McDonald S, Sebastian S, McLoughlin R, Buckley M, O'Connor H, O'Morain C. Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease. Scand. J. Gastroenterol. 42: 194-199 (2007). *

• Quan J, Piao L, Wang X, Li T, Yin X. Rossicaside B protects against carbon tetrachloride-induced hepatotoxicity in mice. Basic Clin. Pharmacol. Toxicol. 105: 380-386 (2009).

• Quan J, Yin X, Xu H. Boschniakia rossica prevents the carbon tetrachloride-induced hepatotoxicity in rat. Exp. Toxicol. Pathol. Oct 14 [Epub ahead of print] (2009).

• Quigley EM, Marsh MN, Shaffer JL, Markin RS. Hepatobiliary complications of total parenteral nutrition. Gastroenterology 104: 286-301 (1993).

• Rahhal RM, Bishop WP. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm. Bowel Dis. 14: 1678-1682 (2008). *

• Rahier JF, Rahier J, Leclercq I, Geubel AP. Severe acute cholestatic hepatitis with prolonged cholestasis and bile-duct injury following atorvastatin therapy: a case report. Acta Gastroenterol. Belg. 71: 318-320 (2008).

• Ramakers BP, de Goeij M, van der Hoeven JG, Peters WH, Pickkers P. Inflammation-induced hepatotoxicity in humans. Shock 31: 151-156 (2009).

• Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst. Rev. 3: CD002148 (2001). *

• Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases - a systematic Cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am. J. Gastroenterol. 100: 2583-2591 (2005). *

• Ramm GA, Ruddell RG. Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. Semin. Liver Dis. 25: 433-449 (2005).

• Ramos R, Mascarenhas J, Duarte P, Vicente C, Casteleiro C. Conjugated linoleic acid-induced toxic hepatitis: first case report. Dig. Dis. Sci. 54: 1141-1143 (2009). *

• Ramos-Casals M, Sanchez-Tapias JM, Pares A, Forns X, Brito-Zeron P, Nardi N, Vazquez P, Velez D, Arias I, Bove A, Plaza J, Rodes J, Font J. Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjogren's syndrome. J. Rheumatol. 33: 1593-1599 (2006).

• Ranganathan P, Culverhouse R, Marsh S, Mody A, Scott-Horton TJ, Brasington R, Joseph A, Reddy V, Eisen S, McLeod HL. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J. Rheumatol. 35: 572-579 (2008).

• Rauchschwalbe SK, Zuhlsdorf MT, Wensing G, Kuhlmann J. Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype. Int. J. Clin. Pharmacol. Ther. 42: 73-77 (2004).

• Ray SD, Parmar M, Syed I, Rathod J, Zinkovsky D, Bulku E, Gigliotti J, Hackman RM, Stohs SJ. Long term exposure effect of a unique metabolic nutrition system containing a diverse group of phytochemicals on serum chemistry and genomic and non-genomic changes in the liver of female B6C3F1 mice. Phytother. Res. 22: 458-471 (2008). *

• Reinhardt M, Machnik G, Krombholz B, Jahn G. The so-called dihydralazine hepatitis. A contribution to the pathogenesis. Dtsch. Z. Verdau. Stoffwechselkr. 45: 283-294 (1985).

• Reinshagen M, Schutz Dagger E, Armstrong VW, Behrens C, von Tirpitz C, Stallmach A, Herfarth H, Stein J, Bias P, Adler G, Shipkova M, Kruis W, Oellerich M, von Ahsen N. 6-Thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial. Clin. Chem. 53: 1306-1314 (2007). *

• Renna MS, Correa SG, Porporatto C, Figueredo CM, Aoki MP, Paraje MG, Sotomayor CE. Hepatocellular apoptosis during Candida albicans colonization: involvement of TNF-alpha and infiltrating Fas-L positive lymphocytes. Int. Immunol. 18: 1719-1728 (2006). *

• Reyes H, Ribalta J, Hernandez I, Arrese M, Pak N, Wells M, Kirsch RE. Is dietary erucic acid hepatotoxic in pregnancy? An experimental study in rats and hamsters. Hepatology 21: 1373-1379 (1995).

• Reyes H, Zapata R, Hernandez I, Gotteland M, Sandoval L, Jiron MI, Palma J, Almuna R, Silva JJ. Is a leaky gut involved in the pathogenesis of intrahepatic cholestasis of pregnancy? Hepatology 43: 715-722 (2006). *

• Reyes-Gordillo K, Segovia J, Shibayama M, Vergara P, Moreno MG, Muriel P. Curcumin protects against acute liver damage in the rat by inhibiting NF-kappaB, proinflammatory cytokines production and oxidative stress. Biochim. Biophys. Acta 1770: 989-996 (2007). *

• Reynolds ES, Moslen MT. Damage to hepatic cellular membranes by chlorinated olefins with emphasis on synergism and antagonism. Environ. Health Perspect. 21: 137-147 (1977). *

• Reynolds ES, Moslen MT. Metabolic activation and hepatotoxicity of trichloroethylene. Adv. Exp. Med. Biol. 136: 693-701 (1981).

• Rezzani R. Exploring cyclosporine A-side effects and the protective role-played by antioxidants: the morphological and immunohistochemical studies. Histol. Histopathol. 21: 301-316 (2006).

• Ritland S, Skrede S, Johansen O. A long-term follow-up study of the hepatic copper and serum ceruloplasmin concentrations in patients with chronic liver disease. Scand. J. Gastroenterol. 17: 545-551 (1982).

• Roberts EA. Non-alcoholic steatohepatitis in children. Clin. Liver Dis.11: 155-172 (2007).

• Roberts EA. Steatohepatitis in children. Best Pract. Res. Clin. Gastroenterol. 16: 749-765 (2002).

• Roberts EA, Sarkar B. Liver as a key organ in the supply, storage, and excretion of copper. Am. J. Clin. Nutr. 88: 851S-854S (2008). *

• Robles M, Andrade R. Hepatotoxicity by antibiotics: update in 2008. Rev. Esp. Quimioter. 21: 224-233 (2008).

• Rochling FA, Zetterman RK. Do hepatotoxicity registries have a role in health care? Gastroenterology 135: 1847-1850 (2008). *

• Roeder E. Medicinal plants in China containing pyrrolizidine alkaloids. Pharmazie 55: 711-726 (2000).

• Rohacova J, Marin ML, Martinez-Romero A, Diaz L, O'Connor JE, Gomez-Lechon MJ, Donato MT, Castell JV, Miranda MA. Fluorescent benzofurazan-cholic acid conjugates for in vitro assessment of bile acid uptake and its modulation by drugs. ChemMedChem. 4: 466-472 (2009).

• Ros JE, Roskams TA, Geuken M, Havinga R, Splinter PL, Petersen BE, LaRusso NF, van der Kolk DM, Kuipers F, Faber KN, Muller M, Jansen PL. ATP binding cassette transporter gene expression in rat liver progenitor cells. Gut 52: 1060-1067 (2003). *

• Rosenthal P. Digestive disease week 2000. American association for the study of liver diseases. IDrugs 3: 868-871 (2000).

• Roth RA, Harkema JR, Pestka JP, Ganey PE. Is exposure to bacterial endotoxin a determinant of susceptibility to intoxication from xenobiotic agents? Toxicol. Appl. Pharmacol. 147: 300-311 (1997). *

• Rouisse L, Chakrabarti SK. Dose-dependent metabolism of trichloroethylene and its relevance to hepatotoxicity in rats. Environ. Res. 40: 450-458 (1986).

• Roznak D, Halevy A, Orda R. Liver damage after exposure to halothane. Harefuah. 118: 455-456 (1990).

• Rubin RA, Kowalski TE, Khandelwal M, Malet PF. Ursodiol for hepatobiliary disorders. Ann. Intern. Med. 121: 207-218 (1994). *

• Rudnick DA, Liao Y, An JK, Muglia LJ, Perlmutter DH, Teckman JH. Analyses of hepatocellular proliferation in a mouse model of alpha-1-antitrypsin deficiency. Hepatology 39: 1048-1055 (2004). *

• Rudnick DA, Shikapwashya O, Blomenkamp K, Teckman JH. Indomethacin increases liver damage in a murine model of liver injury from alpha-1-antitrypsin deficiency. Hepatology 44: 976-982 (2006). *

• Ruepp S, Boess F, Suter L, de Vera MC, Steiner G, Steele T, Weiser T, Albertini S. Assessment of hepatotoxic liabilities by transcript profiling. Toxicol. Appl. Pharmacol. 207: S161-S170 (2005). *

• Rulyak SJ, Saunders MD, Lee SD. Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease. J. Clin. Gastroenterol. 36: 234-237 (2003).

• Rumbo C, Emerick KM, Emre S, Shneider BL. Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report. J. Pediatr. Gastroenterol. Nutr. 35: 391-398 (2002). *

• Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 10: 1018-1023 (2004). *

• Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin. Liver Dis. 29: 412-422 (2009).

• Rutgeerts PJ. Conventional treatment of Crohn's disease: objectives and outcomes. Inflamm. Bowel Dis. 7 Suppl. 1: S2-S8 (2001). *

• Saha B, Nandi D. Farnesyltransferase inhibitors reduce Ras activation and ameliorate acetaminophen-induced liver injury in mice. Hepatology 50: 1547-1557 (2009).

• Saha S, New LS, Kiat HH, Chui WK, Chan EC. Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity. Toxicol. Lett. 192: 141-149 (2010).

• Sahi J, Sinz MW, Campbell S, Mireles R, Zheng X, Rose KA, Raeissi S, Hashim MF, Ye Y, de Morais SM, Black C, Tugnait M, Keller LH. Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034. Chem. Biol. Interact. 159: 156-168 (2006). *

• Saini SP, Sonoda J, Xu L, Toma D, Uppal H, Mu Y, Ren S, Moore DD, Evans RM, Xie W. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol. Pharmacol. 65: 292-300 (2004). *

• Saito C, Zwingmann C, Jaeschke H. Novel mechanisms of protection against acetaminophen hepatotoxicity in mice by glutathione and N-acetylcysteine. Hepatology 51: 246-254 (2010). *

• Saito H, Osumi M, Hirano H, Shin W, Nakamura R, Ishikawa T. Technical pitfalls and improvements for high-speed screening and QSAR analysis to predict inhibitors of the human bile salt export pump (ABCB11/BSEP). AAPS J. 11: 581-589 (2009).

• Sakurai A, Kurata A, Onishi Y, Hirano H, Ishikawa T. Prediction of drug-induced intrahepatic cholestasis: in vitro screening and QSAR analysis of drugs inhibiting the human bile salt export pump. Expert Opin. Drug Saf. 6: 71-86 (2007).

• Sanchez Hellín V, Gutierrez Rodero F. Toxicogenetics of antiretroviral treatment (II): neurotoxicity, hepatotoxicity, lactic acidosis, kidney damage, and other adverse effects of antiretroviral drugs. Enferm. Infecc. Microbiol. Clin. 26 Suppl. 6: 24-33 (2008).

• Sarkar J, Qi C, Guo D, Ahmed MR, Jia Y, Usuda N, Viswakarma N, Rao MS, Reddy JK. Transcription coactivator PRIP, the peroxisome proliferator-activated receptor (PPAR)-interacting protein, is redundant for the function of nuclear receptors PPARalpha and CAR, the constitutive androstane receptor, in mouse liver. Gene Expr. 13: 255-269 (2007).

• Sarva RP, Fromm H, Farivar S, Sembrat RF, Mendelow H, Shinozuka H, Wolfson SK. Comparison of the effects between ursodeoxycholic and chenodeoxycholic acids on liver function and structure and bile acid composition in the Rhesus Monkey. Gastroenterology 79: 629-636 (1980).

• Satoh M, Ando S, Shinoda T, Yamazaki M. Clearance of bacterial lipopolysaccharides and lipid A by the liver and the role of argininosuccinate synthase. Innate Immun. 14: 51-60 (2008). *

• Sauter G, Beuers U, Paumgartner G. Effect of dietary fiber on serum bile acids in patients with chronic cholestatic liver disease under ursodeoxycholic acid therapy. Digestion 56: 523-527 (1995).

• Savidou I, Deutsch M, Soultati AS, Koudouras D, Kafiri G, Dourakis SP. Hepatotoxicity induced by cyproterone acetate: a report of three cases. World J. Gastroenterol. 12: 7551-7555 (2006). *

• Scatena R, Bottoni P, Martorana GE, Vincenzoni F, Botta G, Pastore P, Giardina B. Mitochondria, ciglitazone and liver: a neglected interaction in biochemical pharmacology. Eur. J. Pharmacol. 567: 50-58 (2007). *

• Schiano TD. Hepatotoxicity and complementary and alternative medicines. Clin. Liver Dis. 7: 453-473 (2003).

• Schmassmann A, Angellotti MA, Clerici C, Hofmann AF, Ton-Nu HT, Schteingart CD, Marcus SN, Hagey LR, Rossi SS, Aigner A. Transport, metabolism, and effect of chronic feeding of lagodeoxycholic acid. A new, natural bile acid. Gastroenterology 99: 1092-1104 (1990).

• Schmassmann A, Hofmann AF, Angellotti MA, Ton-Nu HT, Schteingart CD, Clerici C, Rossi SS, Rothschild MA, Cohen BI, Stenger RJ, et al. Prevention of ursodeoxycholate hepatotoxicity in the rabbit by conjugation with N-methyl amino acids. Hepatology 11: 989-996 (1990).

• Schmidt LE. Age and paracetamol self-poisoning. Gut 54: 686-690 (2005). *

• Schoepfer AM, Engel A, Fattinger K, Marbet UA, Criblez D, Reichen J, Zimmermann A, Oneta CM. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife((R)) products. J. Hepatol. 47: 521-526 (2007). *

• Schoonen W, Kloks C, Ploemen JP, Smit M, Zandberg P, Horbach G, Mellema J, Thijssen-van Zuylen C, Tas A, van Nesselrooij J, Vogels J. Uniform procedure of 1H NMR analysis of rat urine and toxico-metabonomics. Part II: comparison of NMR profiles for classification of hepatotoxicity. Toxicol. Sci. 98: 286-297 (2007). *

• Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, Lamba J, Kim RB, Ramachandran V, Komoroski BJ, Venkataramanan R, Cai H, Sinal CJ, Gonzalez FJ, Schuetz JD. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J. Biol. Chem. 276: 39411-39418 (2001). *

• Schuppan D, Jia JD, Brinkhaus B, Hahn EG. Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 30: 1099-1104 (1999). *

• Schwarzenberg SJ, Bundy M. Ursodeoxycholic acid modifies gut-derived endotoxemia in neonatal rats. Pediatr. Res. 35: 214-217 (1994).

• Seiderer J, Zech CJ, Diebold J, Schoenberg SO, Brand S, Tillack C, Goke B, Ochsenkuhn T. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur. J. Gastroenterol. Hepatol. 18: 553-555 (2006).

• Selcoki Y, Uz E, Bayrak R, Sahin S, Kaya A, Uz B, Karanfil A, Ozkara A, Akcay A. The protective effect of erdosteine against cyclosporine A-induced cardiotoxicity in rats. Toxicology 239: 53-59 (2007). *

• Senior JR. What is idiosyncratic hepatotoxicity? What is it not? Hepatology 47: 1813-1815 (2008). *

• Sennello JA, Fayad R, Morris AM, Eckel RH, Asilmaz E, Montez J, Friedman JM, Dinarello CA, Fantuzzi G. Regulation of T cell-mediated hepatic inflammation by adiponectin and leptin. Endocrinology 146: 2157-2164 (2005). *

• Setchell KD, Schwarz M, O'Connell NC, Lund EG, Davis DL, Lathe R, Thompson HR, Weslie Tyson R, Sokol RJ, Russell DW. Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease. J. Clin. Invest. 102: 1690-1703 (1998). *

• Seth AK, Badminton MN, Mirza D, Russell S, Elias E. Liver transplantation for porphyria: who, when, and how? Liver Transpl. 13: 1219-1227 (2007). *

• Shah S, Ali L, Sattar RA, Aziz T, Ansari T, Ara J. Malarial hepatopathy in falciparum malaria. J. Coll. Physicians Surg. Pak. 19: 367-370 (2009).

• Shan W, Palkar PS, Murray IA, McDevitt EI, Kennett MJ, Kang BH, Isom HC, Perdew GH, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by down-regulating pro-inflammatory gene expression. Toxicol. Sci. 105: 418-428 (2008). *

• Sharma OP, Sharma S, Pattabhi V, Mahato SB, Sharma PD. A review of the hepatotoxic plant Lantana camara. Crit. Rev. Toxicol. 37: 313-352 (2007).

• Sharma RP, He Q, Riley RT. Lupus-prone NZBWF1/J mice, defective in cytokine signaling, are resistant to fumonisin hepatotoxicity despite accumulation of liver sphinganine. Toxicology 216: 59-71 (2005). *

• Shaw PJ, Beggs KM, Sparkenbaugh EM, Dugan CM, Ganey PE, Roth RA. Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity. Toxicol. Sci. 111: 288-301 (2009). *

• Shaw PJ, Ganey PE, Roth RA. Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure. J. Pharmacol. Exp. Ther. 328: 62-68 (2009). *

• Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 79: 7478-7491 (2005). *

• Shaye OA, Yadegari M, Abreu MT, Poordad F, Simon K, Martin P, Papadakis KA, Ippoliti A, Vasiliauskas E, Tran TT. Hepatotoxicity of 6-mercaptopurine (6-MP) and azathioprine (AZA) in adult IBD patients. Am. J. Gastroenterol. 102: 2488-2494 (2007). *

• Shear NH. Fulfilling an unmet need in psoriasis: do biologicals hold the key to improved tolerability? Drug Saf. 29: 49-66 (2006).

• Shen C, Meng Q, Zhang G, Hu W. Rifampicin exacerbates isoniazid-induced toxicity in human but not in rat hepatocytes in tissue-like cultures. Br. J. Pharmacol. 153: 784-791 (2008). *

• Sherlock S. The spectrum of hepatotoxicity due to drugs. Lancet 2: 440-444 (1986).

• Shibayama Y, Hashimoto K, Nakata K. Relation of the reticuloendothelial function to endotoxin hepatotoxicity. Exp. Pathol. 43: 173-179 (1991).

• Shinozaki K, Ebert O, Woo SL. Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology 41: 196-203 (2005). *

• Shiratori Y, Tanaka M, Hai K, Kawase T, Shirna S, Sugimoto T. Role of endotoxin-responsive macrophages in hepatic injury. Hepatology 11: 183-192 (1990).

• Shulman HM, McDonald GB. Chapter 31. Hepatic complications of hematopoietic cell transplantation. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 409-421 (2007). *

• Siebler J, Galle PR. Treatment of nonalcoholic fatty liver disease. World J. Gastroenterol. 12: 2161-2167 (2006). *

• Silva VM, Hennig GE, Manautou JE. Cholestasis induced by model organic anions protects from acetaminophen hepatotoxicity in male CD-1 mice. Toxicol. Lett. 160: 204-211 (2005). *

• Silva VM, Thibodeau MS, Chen C, Manautou JE. Transport deficient (TR(-)) hyperbilirubinemic rats are resistant to acetaminophen hepatotoxicity. Biochem. Pharmacol. 70: 1832-1839 (2005). *

• Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284: 1247-1255 (2000). *

• Simko V, Kelley RE, Dincsoy HP, Gimmon Z, Willmann K. Exercise in rats with liver injury induced by carbon tetrachloride or bile duct obstruction. Blood cholic acid and liver histology. Res. Exp. Med. (Berl.) 181: 135-145 (1982).

• Simko V, Michael S. Effect of ursodeoxycholic acid on in vivo and in vitro toxic liver injury in rats. Aliment. Pharmacol. Ther. 8: 315-322 (1994).

• Singer SS, Dravis D, Henkels K, Trulzsch DV. Fatty acid binding protein inhibits glycolithocholate sulfation. Biochem. Int. 27: 373-383 (1992).

• Sinha A, Clatch RJ, Stuck G, Blumenthal SA, Patel SA. Isoflurane hepatotoxicity: a case report and review of the literature. Am. J. Gastroenterol. 91: 2406-2409 (1996).

• Skakun NP, Tabachuk OE. The comparative action of isoniazid, rifampicin and ethambutol on liver function. Eksp. Klin. Farmakol. 55: 45-47 (1992).

• Sniderman AD. Is there value in liver function test and creatine phosphokinase monitoring with statin use? Am. J. Cardiol. 94: 30F-34F (2004).

• Snow KL, Moseley RH. Effect of thiazolidinediones on bile acid transport in rat liver. Life Sci. 80: 732-740 (2007). *

• Solaas K, Kase BF, Pham V, Bamberg K, Hunt MC, Alexson SE. Differential regulation of cytosolic and peroxisomal bile acid amidation in mouse liver: PPARalpha activation favors formation of unconjugated bile acids. J. Lipid Res. 45: 1051-1060 (2004). *

• Song Z, McClain CJ, Chen T. S-Adenosylmethionine protects against acetaminophen-induced hepatotoxicity in mice. Pharmacology 71: 199-208 (2004).

• Song Z, Zhou Z, Chen T, Hill D, Kang J, Barve S, McClain C. S-Adenosylmethionine (SAMe) protects against acute alcohol induced hepatotoxicity in mice. J. Nutr. Biochem. 14: 591-597 (2003). *

• Song Z, Zhou Z, Uriarte S, Wang L, Kang YJ, Chen T, Barve S, McClain CJ. S-Adenosylhomocysteine sensitizes to TNF-alpha hepatotoxicity in mice and liver cells: a possible etiological factor in alcoholic liver disease. Hepatology 40: 989-997 (2004). *

• Soni MG, Mangipudy RS, Mumtaz MM, Mehendale HM. Tissue repair response as a function of dose during trichloroethylene hepatotoxicity. Toxicol. Sci. 42: 158-165 (1998).

• Sonoda J, Xie W, Rosenfeld JM, Barwick JL, Guzelian PS, Evans RM. Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc. Natl. Acad. Sci. U.S.A. 99: 13801-13806 (2002). *

• Soza A, Riquelme F, Alvarez M, Duarte I, Glasinovic JC, Arrese M. Hepatotoxicity by amoxicillin/clavulanic acid: case report. Rev. Med. Chil. 127: 1487-1491 (1999).

• Srivastava S, Younossi ZM. Morbid obesity, nonalcoholic fatty liver disease, and weight loss surgery. Hepatology 42: 490-492 (2005). *

• Stacey NH. Toxicity of mixtures of trichloroethylene, tetrachloroethylene and 1,1,1-trichloroethane: similarity of in vitro to in vivo responses. Toxicol. Ind. Health 5: 441-450 (1989).

• Stadlbauer V, Fickert P, Lackner C, Schmerlaib J, Krisper P, Trauner M, Stauber RE. Hepatotoxicity of NONI juice: report of two cases. World J. Gastroenterol. 11: 4758-4760 (2005). *

• Stamp L, Roberts R, Kennedy M, Barclay M, O'Donnell J, Chapman P. The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomed. Pharmacother. 60: 678-687 (2006).

• Stedman C. Herbal hepatotoxicity. Semin. Liver Dis. 22: 195-206 (2002).

• Steup DR, Hall P, McMillan DA, Sipes IG. Time course of hepatic injury and recovery following coadministration of carbon tetrachloride and trichloroethylene in Fischer-344 rats. Toxicol. Pathol. 21: 327-334 (1993).

• Steup DR, Wiersma D, McMillan DA, Sipes IG. Pretreatment with drinking water solutions containing trichloroethylene or chloroform enhances the hepatotoxicity of carbon tetrachloride in Fischer 344 rats. Fundam. Appl. Toxicol. 16: 798-809 (1991).

• Stickel F, Droz S, Patsenker E, Bogli-Stuber K, Aebi B, Leib SL. Severe hepatotoxicity following ingestion of Herbalife((R)) nutritional supplements contaminated with Bacillus subtilis. J. Hepatol. 50: 111-117 (2009). *

• Stickel F, Hoehn B, Schuppan D, Seitz HK. Review article: nutritional therapy in alcoholic liver disease. Aliment. Pharmacol. Ther. 18: 357-373 (2003). *

• Stickel F, Patsenker E, Schuppan D. Herbal hepatotoxicity. J. Hepatol. 43: 901-910 (2005). *

• Stickel F, Poschl G, Seitz HK, Waldherr R, Hahn EG, Schuppan D. Acute hepatitis induced by greater celandine (Chelidonium majus). Scand. J. Gastroenterol. 38: 565-568 (2003). *

• Stickel F, Seitz HK. The efficacy and safety of comfrey. Public Health Nutr. 3: 501-508 (2000).

• Stickel F, Seitz HK, Hahn EG, Schuppan D. Liver toxicity of drugs of plant origin. Z. Gastroenterol. 39: 225-232, 234-237 (2001).

• Stiehl A. Pathophysiology of cholestasis: correlation between bile acid metabolism and liver damage. Z. Gastroenterol. 30 Suppl. 1: 46-48 (1992).

• Stokkeland K, Hilm G, Spak F, Franck J, Hultcrantz R. Different drinking patterns for women and men with alcohol dependence with and without alcoholic cirrhosis. Alcohol Alcohol. 43: 39-45 (2008). *

• Su GL, Gong KQ, Fan MH, Kelley WM, Hsieh J, Sun JM, Hemmila MR, Arbabi S, Remick DG, Wang SC. Lipopolysaccharide-binding protein modulates acetaminophen-induced liver injury in mice. Hepatology 41: 187-195 (2005). *

• Su L, Xu J, Ji BX, Wan SG, Lu CY, Dong HQ, Yu YY, Lu DP. Autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Int. J. Hematol. 84: 276-281 (2006).

• Suchin SM, Wolf DC, Lee Y, Ramaswamy G, Sheiner PA, Facciuto M, Marvin MR, Kim-Schluger L, Lebovics E. Potentiation of acetaminophen hepatotoxicity by phenytoin, leading to liver transplantation. Dig. Dis. Sci. 50: 1836-1838 (2005). *

• SugiyamaY, Maeda K. Assessment of inhibitory effect of many therapeutically important drugs on bile acid transport by NTCP, BSEP and other transporters. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 36-37 (2006). *

• Sun F, Chen Y, Xiang Y, Zhan S. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int. J. Tuberc. Lung Dis. 12: 994-1002 (2008).

• Tafazoli S, O'Brien PJ. Accelerated cytotoxic mechanism screening of hydralazine using an in vitro hepatocyte inflammatory cell peroxidase model. Chem. Res. Toxicol. 21: 904-910 (2008). *

• Tagle A M DR. Hepatobiliary infections in AIDS. Rev. Gastroenterol. Peru 17: 107-114 (1997).

• Tagle AM, Vega DJ, Scavino LY, Luna CE. Overlap syndrome between autoimmune hepatitis and primary biliary cirrhosis: report of a case. Rev. Gastroenterol. Peru 24: 349-352 (2004).

• Tahan G, Tarcin O, Tahan V, Eren F, Gedik N, Sahan E, Biberoglu N, Guzel S, Bozbas A, Tozun N, Yucel O. The effects of N-acetylcysteine on bile duct ligation-induced liver fibrosis in rats. Dig. Dis. Sci. 52: 3348-3354 (2007). *

• Taieb D, Malicet C, Garcia S, Rocchi P, Arnaud C, Dagorn JC, Iovanna JL, Vasseur S. Inactivation of stress protein p8 increases murine carbon tetrachloride hepatotoxicity via preserved CYP2E1 activity. Hepatology 42: 176-182 (2005). *

• Talwalkar JA, Souto E, Jorgensen RA, Lindor KD. Natural history of pruritus in primary biliary cirrhosis. Clin. Gastroenterol. Hepatol. 1: 297-302 (2003). *

• Tam S, Carroll W. Allopurinol hepatotoxicity. Am. J. Med. 86: 357-358 (1989).

• Tan HH, Fiel MI, Del Rio Martin J, Schiano TD. Graft rejection occurring in post-liver transplant patients receiving cytotoxic chemotherapy: a case series. Liver Transpl. 15: 634-639 (2009).

• Tanaka Y, Aleksunes LM, Cui YJ, Klaassen CD. ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2 dependent and independent signaling. Toxicol. Sci. 108: 247-257 (2009). *

• Tandra S, Vuppalanchi R. Use of statins in patients with liver disease. Curr. Treat. Options Cardiovasc. Med. 11: 272-278 (2009).

• Tang W. Drug metabolite profiling and elucidation of drug-induced hepatotoxicity. Expert Opin. Drug Metab. Toxicol. 3: 407-420 (2007).

• Taniai N, Akimaru K, Ishikawa Y, Kanada T, Kakinuma D, Mizuguchi Y, Mamada Y, Yoshida H, Tajiri T. Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation. J. Nippon Med. Sch. 75: 187-191 (2008). *

• Tannapfel A, Reinacher-Schick A. Chemotherapy associated hepatotoxicity in the treatment of advanced colorectal cancer (CRC). Z. Gastroenterol. 46: 435-440 (2008).

• Tarantino G, Di Minno MN, Capone D. Drug-induced liver injury: is it somehow foreseeable? World J. Gastroenterol. 15: 2817-2833 (2009). *

• Tasduq SA, Peerzada K, Koul S, Bhat R, Johri RK. Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin. Hepatol. Res. 31: 132-135 (2005).

• Tavill AS, Qadri AM. Alcohol and iron. Semin. Liver Dis. 24: 317-325 (2004).

• Taylor WJ, Korendowych E, Nash P, Helliwell PS, Choy E, Krueger GG, Soriano ER, McHugh NJ, Rosen CF. Drug use and toxicity in psoriatic disease: focus on methotrexate. J. Rheumatol. 35: 1454-1457 (2008).

• Te HS. Cholestasis in HIV-infected patients. Clin. Liver Dis. 8: 213-228 (2004).

• Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am. J. Gastroenterol. 95: 3150-3156 (2000). *

• Tehrani R, Nash-Goelitz A, Adams E, Dahiya M, Eilers D. Minocycline-induced cutaneous polyarteritis nodosa. J. Clin. Rheumatol. 13: 146-149 (2007).

• Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin. Pharmacokinet. 46: 187-208 (2007).

• Teml A, Schwab M, Harrer M, Miehsler W, Schaeffeler E, Dejaco C, Mantl M, Schneider B, Vogelsang H, Reinisch W. A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis. Scand. J. Gastroenterol. 40: 1205-1213 (2005). *

• Teml A, Schwab M, Hommes DW, Almer S, Lukas M, Feichtenschlager T, Florin T, Seiderer J, Petritsch W, Bokemeyer B, Kreisel W, Herrlinger KR, Knoflach P, Bonaz B, Klugmann T, Herfarth H, Pedarnig N, Reinisch W. A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease. Wien. Klin. Wochenschr. 119: 519-526 (2007). *

• Tenenbaum A, Fisman EZ, Motro M, Adler Y. Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Adv. Cardiol. 45: 127-153 (2008).

• Teng S, Piquette-Miller M. Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis. Br. J. Pharmacol. 151: 367-376 (2007). *

• Teoh NC, Farrell GC. Hepatotoxicity associated with non-steroidal anti-inflammatory drugs. Clin. Liver Dis. 7: 401-413 (2003).

• Teschke R. Hepatotoxicity by drugs and dietary supplements: safety perspectives on clinical and regulatory issues. Ann. Hepatol. 8: 184-195 (2009).

• Teschke R, Bahre R. Severe hepatotoxicity by Indian Ayurvedic herbal products: a structured causality assessment. Ann. Hepatol. 8: 258-266 (2009).

• Teschke R, Schwarzenboeck A. Suspected hepatotoxicity by Cimicifugae racemosae rhizoma (black cohosh, root): critical analysis and structured causality assessment. Phytomedicine 16: 72-84 (2009).

• Teschke R, Schwarzenboeck A, Akinci A. Kava hepatotoxicity: a European view. N. Z. Med. J. 121: 90-98 (2008).

• Thomas JA, Aithal GP. Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary? Am. J. Clin. Dermatol. 6: 357-363 (2005).

• Thompson MB. Bile acids in the assessment of hepatocellular function. Toxicol. Pathol. 24: 62-71 (1996). *

• Thulin P, Rafter I, Stockling K, Tomkiewicz C, Norjavaara E, Aggerbeck M, Hellmold H, Ehrenborg E, Andersson U, Cotgreave I, Glinghammar B. PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes. Toxicol. Appl. Pharmacol. 231: 1-9 (2008). *

• Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin. Drug Investig. 26: 55-62 (2006).

• Timbrell JA, Seabra V, Waterfield CJ. The in vivo and in vitro protective properties of taurine. Gen. Pharmacol. 26: 453-462 (1995). *

• Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin. Rheumatol. 26: 578-581 (2007). *

• Tolia V, Nilsson HO, Boyer K, Wuerth A, Al-Soud WA, Rabah R, Wadstrom T. Detection of Helicobacter ganmani-like 16S rDNA in pediatric liver tissue. Helicobacter 9: 460-468 (2004). *

• Tomasevic R, Golubovic G, Kiurski M, Pavlovic A. Cholestatic syndrome in patients with systemic erythematous lupus - differential diagnostic aspects Med. Pregl. 61: 291-294 (2008).

• Toscano E, Cotta J, Robles M, Lucena MA, Andrade RJ. Hepatotoxicity induced by new immunosuppressants. Gastroenterol. Hepatol. Nov 2 [Epub ahead of print] (2009).

• Tozzi V, Libertone R, Liuzzi G. HIV pharmacogenetics in clinical practice: recent achievements and future challenges. Curr. HIV Res. 6: 544-554 (2008).

• Tu QV, Okoli AS, Kovach Z, Mendz GL. Hepatocellular carcinoma: prevalence and molecular pathogenesis of Helicobacter spp. Future Microbiol. 4: 1283-1301 (2009).

• Tucker WE Jr. Preclinical toxicology of bupropion: an overview. J. Clin. Psychiatry 44: 60-62 (1983).

• Tukov FF, Luyendyk JP, Ganey PE, Roth RA. The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury. Toxicol. Sci. 100: 267-280 (2007). *

• Tyson CA, Hawk-Prather K, Story DL, Gould DH. Correlations of in vitro and in vivo hepatotoxicity for five haloalkanes. Toxicol. Appl. Pharmacol. 70: 289-302 (1983).

• Uchiyama A, Kim JS, Kon K, Jaeschke H, Ikejima K, Watanabe S, Lemasters JL. Translocation of iron from lysosomes into mitochondria is a key event during oxidative stress-induced hepatocellular injury. Hepatology 48: 1644-1654 (2008). *

• Ulbricht C, Chao W, Costa D, Rusie-Seamon E, Weissner W, Woods J. Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. Curr. Drug Metab. 9: 1063-1120 (2008).

• Umar RK, Rinella ME. An update on nonalcoholic fatty liver disease. Gastroenterology & Hepatology Annual Review Vol. 1, June 2006, p. 94-98 (2006). *

• Uppal H, Saini SP, Moschetta A, Mu Y, Zhou J, Gong H, Zhai Y, Ren S, Michalopoulos GK, Mangelsdorf DJ, Xie W. Activation of LXRs prevents bile acid toxicity and cholestasis in female mice. Hepatology 45: 422-432 (2007). *

• Uraz S, Tahan V, Aygun C, Eren F, Unluguzel G, Yuksel M, Senturk O, Avsar E, Haklar G, Celikel C, Hulagu S, Tozun N. Role of ursodeoxycholic acid in prevention of methotrexate-induced liver toxicity. Dig. Dis. Sci. 53: 1071-1077 (2008). *

• Urbanek P. Immunological aspects of alcoholic liver disease. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 32-35. September 12 - 13 (2003). *

• Vaccarino AL, Paul D, Mukherjee PK, Rodriguez de Turco EB, Marcheselli VL, Xu L, Trudell ML, Minguez JM, Matia MP, Sunkel C, Alvarez-Builla J, Bazan NG. Synthesis and in vivo evaluation of non-hepatotoxic acetaminophen analogs. Bioorg. Med. Chem. 15: 2206-2215 (2007).

• Valentovic M, Terneus M, Harmon RC, Carpenter AB. S-Adenosylmethionine (SAMe) attenuates acetaminophen hepatotoxicity in C57BL/6 mice. Toxicol. Lett. 154: 165-174 (2004). *

• Van Bodegraven AA, Pena AS. Treatment of extraintestinal manifestations in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 6: 201-212 (2003).

• van der Watt G, Laugharne J, Janca A. Complementary and alternative medicine in the treatment of anxiety and depression. Curr. Opin. Psychiatry 21: 37-42 (2008).

• van Erpecum KJ, van de Meeberg PC, van Berge Henegouwen GP. Rationale for therapy with ursodeoxycholic acid in patients with cholestatic liver disease. Neth. J. Med. 43: 233-238 (1993).

• Van Pelt FN, Carey MA, Carey JB. Chapter 29. Acute and chronic liver diseases induced by drugs or xenobiotics. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 375-388 (2007). *

• Vanderperren B, Rizzo M, Angenot L, Haufroid V, Jadoul M, Hantson P. Acute liver failure with renal impairment related to the abuse of Senna anthraquinone glycosides. Ann. Pharmacother. 39: 1353-1357 (2005).

• Vaquero J, Belanger M, James L, Herrero R, Desjardins P, Cote J, Blei AT, Butterworth RF. Mild hypothermia attenuates liver injury and improves survival in mice with acetaminophen toxicity. Gastroenterology 132: 372-383 (2007). *

• Varghese L, Agarwal C, Tyagi A, Singh RP, Agarwal R. Silibinin efficacy against human hepatocellular carcinoma. Clin. Cancer Res. 11: 8441-8448 (2005). *

• Venkatraman A, Shiva S, Wigley A, Ulasova E, Chhieng D, Bailey SM, Darley-Usmar VM. The role of iNOS in alcohol-dependent hepatotoxicity and mitochondrial dysfunction in mice. Hepatology 40: 565-573 (2004). *

• Verheij J, Voortman J, van Nieuwkerk CM, Jarbandhan SV, Mulder CJ, Bloemena E. Hepatic morphopathologic findings of lead poisoning in a drug addict: a case report. J. Gastrointestin. Liver Dis. 18: 225-227 (2009). *

• Vermes A, Vermes I. Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am. J. Cardiovasc. Drugs 4: 247-255 (2004).

• Vieira FJ, Callado MR, Vieira WP. Abatacept as an option therapy in difficult to treat psoriatic arthritis. Rheumatol. Int. Jul 5 [Epub ahead of print] (2009). *

• Vierling JM. Chapter 30. Clinical use of immunosuppressive drugs to control the immune response. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 391-407 (2007). *

• Villeneuve JP, Pichette V. Cytochrome P450 and liver diseases. Curr. Drug Metab. 5: 273-282 (2004).

• Visalli T, Turkall R, Abdel-Rahman MS. Cocaine hepatotoxicity and its potentiation by lipopolysaccharide: treatment and gender effects. Int. J. Toxicol. 23: 163-170 (2004). *

• Visalli T, Turkall R, Abdel-Rahman MS. Influence of gender on cocaine hepatotoxicity in CF-1 mice. Int. J. Toxicol. 24: 43-50 (2005).

• Visalli T, Turkall R, Abdel-Rahman MS. Gender differences in cocaine pharmacokinetics in CF-1 mice. Toxicol. Lett. 155: 35-40 (2005). *

• Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, Bombardier C, Carmona L, van der Heijde D, Bijlsma JW, Boumpas DT, Canhao H, Edwards CJ, Hamuryudan V, Kvien TK, Leeb BF, Martín-Mola EM, Mielants H, Muller-Ladner U, Murphy G, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in … Ann. Rheum. Dis. 68: 1086-1093 (2009). *

• Voskoboinik I, Greenough M, La Fontaine S, Mercer JF, Camakaris J. Functional studies on the Wilson copper P-type ATPase and toxic milk mouse mutant. Biochem. Biophys. Res. Commun. 281: 966-970 (2001). *

• Voss KA, Liu J, Anderson SP, Dunn C, Miller JD, Owen JR, Riley RT, Bacon CW, Corton JC. Toxic effects of fumonisin in mouse liver are independent of the peroxisome proliferator-activated receptor alpha. Toxicol. Sci. 89: 108-119 (2006). *

• Walisser JA, Glover E, Pande K, Liss AL, Bradfield CA. Aryl hydrocarbon receptor-dependent liver development and hepatotoxicity are mediated by different cell types. Proc. Natl. Acad. Sci. U.S.A. 102: 17858-17863 (2005). *

• Walker NJ, Zurier RB. Liver abnormalities in rheumatic diseases. Clin. Liver Dis. 6: 933-946 (2002).

• Wallace JL. Acetaminophen hepatotoxicity: NO to the rescue. Br. J. Pharmacol. 143: 1-2 (2004). *

• Wallace TM, Veldhuyzen van Zanten SJ. Frequency of use and standards of care for the use of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease: a systematic review of the literature and a survey of Canadian gastroenterologists. Can. J. Gastroenterol. 15: 21-28 (2001). *

• Wang EJ, Casciano CN, Clement RP, Johnson WW. Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm. Res. 20: 537-544 (2003). *

• Wang F, Wen T, Chen XY, Wu H. Protective effects of pirfenidone on D-galactosamine and lipopolysaccharide-induced acute hepatotoxicity in rats. Inflamm. Res. 57: 183-188 (2008). *

• Wang J, Sun R, Wei H, Dong Z, Tian Z. Pre-activation of T lymphocytes by low dose of concanavalin A aggravates Toll-like receptor-3 ligand-induced NK cell-mediated liver injury. Int. Immunopharmacol. 6: 800-807 (2006).

• Wang L, Han Y, Kim CS, Lee YK, Moore DD. Resistance of SHP-null mice to bile acid-induced liver damage. J. Biol. Chem. 278: 44475-44481 (2003). *

• Wang N, Li P, Wang Y, Peng W, Wu Z, Tan S, Liang S, Shen X, Su W. Hepatoprotective effect of Hypericum japonicum extract and its fractions. J. Ethnopharmacol. 116: 1-6 (2008). *

• Wang X, Cederbaum AI. S-Adenosyl-L-methionine decreases the elevated hepatotoxicity induced by Fas agonistic antibody plus acute ethanol pretreatment in mice. Arch. Biochem. Biophys. 477: 1-11 (2008). *

• Wang X, Lu Y, Cederbaum AI. Induction of cytochrome P450 2E1 increases hepatotoxicity caused by Fas agonistic Jo2 antibody in mice. Hepatology 42: 400-410 (2005). *

• Wang YP, Shi B, Chen YX, Xu J, Jiang CF, Xie WF. Drug-induced liver disease: an 8-year study of patients from one gastroenterological department. J. Dig. Dis. 10: 195-200 (2009). *

• Waring JF, Liguori MJ, Luyendyk JP, Maddox JF, Ganey PE, Stachlewitz RF, North C, Blomme EA, Roth RA. Microarray analysis of LPS potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J. Pharmacol. Exp. Ther. 316: 1080-1087 (2006). *

• Warren RB, Griffiths CE. Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clin. Dermatol. 26: 438-447 (2008).

• Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 43: 618-631 (2006). *

• Watkinson G. Sulphasalazine: a review of 40 years' experience. Drugs 32 Suppl. 1: 1-11 (1986).

• Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit. Rev. Toxicol. 33: 105-136 (2003).

• Weiland T, Weiller M, Kunstle G, Wendel A. Sensitization by 5-azacytidine towards death receptor-induced hepatic apoptosis. J. Pharmacol. Exp. Ther. 328: 107-115 (2009). *

• Wiercinska E, Wickert L, Denecke B, Said HM, Hamzavi J, Gressner AM, Thorikay M, ten Dijke P, Mertens PR, Breitkopf K, Dooley S. Id1 is a critical mediator in TGF-beta-induced transdifferentiation of rat hepatic stellate cells. Hepatology 43: 1032-1041 (2006). *

• Wiesner RH, Menon KV. Late hepatic allograft dysfunction. Liver Transpl. 7: 60-73 (2001). *

• Wolf KK, Wood SG, Hunt JA, Walton-Strong BW, Yasuda K, Lan L, Duan SX, Hao Q, Wrighton SA, Jeffery EH, Evans RM, Szakacs JG, von Moltke LL, Greenblatt DJ, Court MH, Scheutz EG, Sinclair PR, Sinclair JF. Role of the nuclear receptor PXR in acetaminophen hepatotoxicity. Drug Metab. Dispos. 33: 1827-1836 (2005). *

• Wolfhagen FH, Vermeulen HG, de Man RA, Lesterhuis W. Initially obscure hepatotoxicity attributed to sildenafil. Eur. J. Gastroenterol. Hepatol. 20: 710-712 (2008).

• Woolf AD. Herbal remedies and children: do they work? Are they harmful? Pediatrics 112: 240-246 (2003). *

• Wright TM, Vandenberg AM. Risperidone- and quetiapine-induced cholestasis. Ann. Pharmacother. 41: 1518-1523 (2007).

• Wu J, Wang C, Liu Q, Yang T, Zhang Q, Peng J, Gao Y, Sun H, Kaku T, Liu K. Protective effect of JBP485 on concanavalin A-induced hepatocyte toxicity in primary cultured rat hepatocytes. Eur. J. Pharmacol. 589: 299-305 (2008).

• Wu Y, Zhang X, Bardag-Gorce F, Robel RC, Aguilo J, Chen L, Zeng Y, Hwang K, French SW, Lu SC, Wan YJ. Retinoid X receptor alpha regulates glutathione homeostasis and xenobiotic detoxification processes in mouse liver. Mol. Pharmacol. 65: 550-557 (2004). *

• Wu YL, Piao DM, Han XH, Nan JX. Protective effects of salidroside against acetaminophen-induced toxicity in mice. Biol. Pharm. Bull. 31: 1523-1529 (2008). *

• Xia L, Yu T. Study of the relationship between the hepatotoxicity and free radical induced by 1,1,2-trichloroethane and 1,1,1-trichloroethane in rat. Biomed. Environ. Sci. 5: 303-313 (1992).

• Xie W, Radominska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES, Waxman DJ, Evans RM. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl. Acad. Sci. U.S.A. 98: 3375-3380 (2001). *

• Xin HW, Xiong H, Wu XC, Li Q, Xiong L, Yu AR. Relationships between thiopurine S-methyltransferase polymorphism and azathioprine-related adverse drug reactions in Chinese renal transplant recipients. Eur. J. Clin. Pharmacol. 65: 249-255 (2009).

• Yamada S, Tang M, Richardson K, Halaschek-Wiener J, Chan M, Cook VJ, Fitzgerald JM, Elwood RK, Brooks-Wilson A, Marra F. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 10: 1433-1445 (2009).

• Yamamoto K, Itoh T, Abe D, Shimizu M, Kanda T, Koyama T, Nishikawa M, Tamai T, Ooizumi H, Yamada S. Identification of putative metabolites of docosahexaenoic acid as potent PPARgamma agonists and antidiabetic agents. Bioorg. Med. Chem. Lett. 15: 517-522 (2005). *

• Yamamoto Y, Moore R, Hess HA, Guo GL, Gonzalez FJ, Korach KS, Maronpot RR, Negishi M. Estrogen receptor alpha mediates 17alpha-ethynylestradiol-causing hepatotoxicity. J. Biol. Chem. 281: 16625-16631 (2006). *

• Yamazaki Y, Kakizaki S, Horiguchi N, Takagi H, Mori M, Negishi M. Role of nuclear receptor CAR in carbon tetrachloride-induced hepatotoxicity. World J. Gastroenterol. 11: 5966-5972 (2005). *

• Yang L, Xiong A, He Y, Wang Z, Wang C, Wang Z, Li W, Yang L, Hu Z. Bile acids metabonomic study on the CCl(4)- and alpha-naphthylisothiocyanate-induced animal models: quantitative analysis of 22 bile acids by ultraperformance liquid chromatography-mass spectrometry. Chem. Res. Toxicol. 21: 2280-2288 (2008). *

• Yee SB, Bourdi M, Masson MJ, Pohl LR. Hepatoprotective role of endogenous interleukin-13 in a murine model of acetaminophen-induced liver disease. Chem. Res. Toxicol. 20: 734-744 (2007). *

• Yeung E, Wong FS, Wanless IR, Shiota K, Guindi M, Joshi S, Gardiner G. Ramipril-associated hepatotoxicity. Arch. Pathol. Lab. Med. 127: 1493-1497 (2003). *

• Yildirim B, Tuncer C, Ergun M, Unal S. Venlafaxine-induced hepatotoxicity in a patient with ulcerative colitis. Ann. Hepatol. 8: 271-272 (2009).

• Yin HQ, Kim YS, Choi YJ, Kim YC, Sohn DH, Ryu SY, Lee BH. Effects of tanshinone IIA on the hepatotoxicity and gene expression involved in alcoholic liver disease. Arch. Pharm. Res. 31: 659-665 (2008).

• Yohe HC, O'Hara KA, Hunt JA, Kitzmiller TJ, Wood SG, Bement JL, Bement WJ, Szakacs JG, Wrighton SA, Jacobs JM, Kostrubsky V, Sinclair PR, Sinclair JF. Involvement of Toll-like receptor 4 in acetaminophen hepatotoxicity. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G1269-G1279 (2006). *

• Yoon KH, Ng SC. Early onset methotrexate-induced pancytopenia and response to G-CSF: a report of two cases. J. Clin. Rheumatol. 7: 17-20 (2001).

• You Q, Cheng L, Reilly TP, Wegmann D, Ju C. Role of neutrophils in a mouse model of halothane-induced liver injury. Hepatology 44: 1421-1431 (2006). *

• Youssef WI, Tavill AS. Connective tissue diseases and the liver. J. Clin. Gastroenterol. 35: 345-349 (2002).

• Yuan L, Kaplowitz N. Glutathione in liver diseases and hepatotoxicity. Mol. Aspects Med. 30: 29-41 (2009).

• Yuan Q, Jonas MM. Pediatric hepatobiliary disease. Curr. Opin. Gastroenterol. 19: 276-280 (2003).

• Yuce B, Gulberg V, Diebold J, Gerbes AL. Hepatitis induced by noni juice from Morinda citrifolia: a rare cause of hepatotoxicity or the tip of the iceberg? Digestion 73: 167-170 (2006). *

• Yue J, Peng R, Chen J, Liu Y, Dong G. Effects of rifampin on CYP2E1-dependent hepatotoxicity of isoniazid in rats. Pharmacol. Res. 59: 112-119 (2009). *

• Yuen MF, Ip P, Ng WK, Lai CL. Hepatotoxicity due to a formulation of Ganoderma lucidum (lingzhi). J. Hepatol. 41: 686-687 (2004). *

• Zabana Y, Domenech E, San Roman AL, Beltran B, Cabriada JL, Saro C, Aramendiz R, Ginard D, Hinojosa J, Gisbert JP, Manosa M, Cabre E, Gassull MA. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflamm. Bowel Dis. 14: 1387-1391 (2008). *

• Zaidi SA. Hepatitis associated with amoxicillin/clavulanic acid and/or ciprofloxacin. Am. J. Med. Sci. 325: 31-33 (2003).

• Zapata Garrido AJ, Romo AC, Padilla FB. Terbinafine hepatotoxicity. A case report and review of literature. Ann. Hepatol. 2: 47-51 (2003). *

• Zelinkova Z, Derijks LJ, Stokkers PC, Vogels EW, van Kampen AH, Curvers WL, Cohn D, van Deventer SJ, Hommes DW. Inosine triphosphate pyrophosphatase and thiopurine S-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin. Gastroenterol. Hepatol. 4: 44-49 (2006). *

• Zhai D, Zhao Y, Chen X, Guo J, He H, Yu Q, Yang J, Davey AK, Wang J. Protective effect of glycyrrhizin, glycyrrhetic acid and matrine on acute cholestasis induced by alpha-naphthyl isothiocyanate in rats. Planta Med. 73: 128-133 (2007).

• Zhang H, Shi Z, Liu Y, Wei Y, Dai J. Lipid homeostasis and oxidative stress in the liver of male rats exposed to perfluorododecanoic acid. Toxicol. Appl. Pharmacol. 227: 16-25 (2008). *

• Zhang J, Huang W, Chua SS, Wei P, Moore DD. Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 298: 422-424 (2002). *

• Zhang J, Huang W, Qatanani M, Evans RM, Moore DD. The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J. Biol. Chem. 279: 49517-49522 (2004). *

• Zou W, Beggs KM, Sparkenbaugh EM, Jones AD, Younis HS, Roth RA, Ganey PE. Sulindac metabolism and synergy with tumor necrosis factor-alpha in a drug-inflammation interaction model of idiosyncratic liver injury. J. Pharmacol. Exp. Ther. 331: 114-121 (2009). *

• Zou W, Devi SS, Sparkenbaugh E, Younis HS, Roth RA, Ganey PE. Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system. Toxicol. Sci. 108: 184-193 (2009). *

Number of references = 906

www psc-literature.org